

Qy 553 DGRGSGYQGDKIMHAIRRLGTFEVDQIEAARQFSKMGFVDNKRIAIWGMGSYGGVTSM 612
 Db 579 DGRGSGYQGDKIMHAIRRLGTFEVDQIEAARQFSKMGFVDNKRIAIWGMGSYGGVTSM 638

Qy 613 VLGGSGSGYFKCGIAAVPSRWEYDSVYSTERMGLPPEDNDHYRNSTVNSRAENFKQV 672
 Db 639 VLGGSGSGYFKCGIAAVPSRWEYDSVYSTERMGLPPEDNDHYRNSTVNSRAENFKQV 698

Qy 673 EYLILHGTAADDNHFQOOSAQISKALVGVDFQAMNYTDEDGIASTAHOHIYTMHF 732
 Db 699 EYLILHGTAADDNHFQOOSAQISKALVGVDFQAMNYTDEDGIASTAHOHIYTMHF 758

Qy 733 IKQCFSLP 740
 Db 759 IKQCFSLP 766

RESULT 33
 ID AAR54613 standard; protein; 739 AA.
 XX
 AC AAR54613;
 XX DT 25-MAR-2003 (revised)
 DT 09-DEC-1994 (first entry)
 XX DB Delta24-34 CD26.
 XX Human; T cell activation antigen; CD26; analogues; deletion; soluble;
 KW signal peptidase; immune-stimulating; response-stimulating; AIDS;
 KW immunosuppression; AIDS-related complex.
 OS Homo sapiens.
 XX
 Key Location/Qualifiers
 FT Misc-difference 23. .24
 /note= "Position of delta24-34 deletion"
 XX WO9409132-A1.
 XX
 PD 28-APR-1994.
 PF 19-AUG-1993; 93WO-US007923.
 XX PR 21-AUG-1992; 92US-00934162.
 PA (DAND) DANA FARBER CANCER INST INC.
 XX PT Morimoto C, Schlossman S, Tanaka T;
 XX WPI; 1994-151317/18.
 DR XX
 PT Polypeptide fragments and analogues of CD26 and encoding nucleic acid -
 PT useful for stimulating immune response, e.g. for treatment of AIDS to
 PT counteract immunosuppressive drug, and as vaccine adjuvant.
 XX
 PS XX
 PT
 PT
 PT
 XX
 PS XX

Claim 4: Page 52-54; 85pp; English.

CC The sequences given in AAP54612-14 represents analogues of the human T
 CC cell activation antigen CD26 which have internal deletions. The analogues
 CC pref. lack residues 3-9 or 24-34. These analogues are soluble under
 CC physiological conditions and lack enough amino acid residues to render
 CC them susceptible to cleavage by signal peptidase. The peptide fragments
 CC and analogues are useful as immune or response-stimulating therapeutics,
 CC eg. they may be useful for treatment of disease conditions characterised by
 CC immunosuppression, eg. AIDS or AIDS-related complex, other virally or
 CC environmentally-induced conditions, and certain congenital immune
 CC deficiencies. The peptides can be employed to increase immune function
 CC which has been impaired by use of immunosuppressive drugs, such as certain
 CC chemotherapeutic drugs. (updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 739 AA;

Query Match 95.5%; Score 3841; DB 2; Length 739;
 Best Local Similarity 97.1%; Pred. No. 0;
 Matches 711; Conservative 0; Mismatches 1; Indels 16; Gaps 1;

Qy 13 SRKTYLTDLYKNTLYKLKSLRWSDHEVLYKQENNLVYNAEGNNSVLENSTPDEF 72
 Db 28 SRKTYLTDLYKNTLYKLKSLRWSDHEVLYKQENNLVYENLYGNSSVLENSTPDEF 87

Qy 73 GHSINDYSISPDGQFILLEYNYVKQWRHSYTASYDIDLNKRQLTIEERIPNNTQWTTWS 132
 Db 88 GHSINDYSISPDGQFILLEYNYVKQWRHSYTASYDIDLNKRQLTIEERIPNNTQWTTWS 147

Qy 133 PVGHKLAQYWWNDIYKIEPNLPSYRITWTGKEDIYNGITDWWYEEVEVSAYSLWWSP 192
 Db 148 PVGHKLAQYWWNDIYKIEPNLPSYRITWTGKEDIYNGITDWWYEEVEVSAYSLWWSP 207

Qy 193 NGTFLAYAQENDTEVPLIEFSYSDSLOQPKTKVTPVYPKAGAVNPVTPVKFVVNTDSLSS 252
 Db 208 NGTFLAYAQENDTEVPLIEFSYSDSLOQPKTKVTPVYPKAGAVNPVTPVKFVVNTDSLSS 267

Qy 253 VTNATSLQITAPASMLIGDHYLCDTWTQPRISLWLRQONYSYMIDCYDESSERWN 312
 Db 268 VTNATSLQITAPASMLIGDHYLCDTWTQPRISLWLRQONYSYMIDCYDESSERWN 327

Qy 313 CLVARQHIELMSTTGWGRFRPSEPHFTLQNSFYKLTISNEFGRHICYFQIDKQDCTFIT 372
 Db 328 CLVARQHIELMSTTGWGRFRPSEPHFTLQNSFYKLTISNEFGRHICYFQIDKQDCTFIT 387

Qy 373 KGTWEVIGIAELTSYDLYIISNEYKGMGPGRNLYK1QSLSDYTKVTCSCLENPERCQYS 432
 Db 388 KGTWEVIGIAELTSYDLYIISNEYKGMGPGRNLYK1QSLSDYTKVTCSCLENPERCQYS 447

Qy 433 VSFSAKAYQYQRCSSGRLPLYTLISSVNDKGRLVLEDNSALDKM1QVNQMPSKLDPF1 492
 Db 448 VSFSAKAYQYQRCSSGRLPLYTLISSVNDKGRLVLEDNSALDKM1QVNQMPSKLDPF1 507

Qy 493 LNETKPYQMLLPPFDKSKKCPPLDLYAGPCSKSOKADTVPLRNWATYLASTENIIVASF 552
 Db 508 LNBTKEWYQMLLPPFDKSKKCPPLDLYAGPCSKSOKADTVPLRNWATYLASTENIIVASF 567

Qy 553 DGRGSGYQGDKIMHAIRRLGTFEVDQIEAARQFSKMGFVDNKRIAIWGMGSYGGVTSM 612
 Db 568 DGRGSGYQGDKIMHAIRRLGTFEVDQIEAARQFSKMGFVDNKRIAIWGMGSYGGVTSM 627

Qy 613 VLGSGSYVFKCGIAVAPSRMEYDVSYTYRMLPTPEDNLHYRNSTMSRAENPKQV 672
 Db 628 VLGSGSYVFKCGIAVAPSRMEYDVSYTYRMLPTPEDNLHYRNSTMSRAENPKQV 687

Qy 673 EYLLIHTGTAADDNHFQOOSAQISKALVGVDFQAMNYTDEDGIASTAHOHIYTMHF 732
 Db 688 EYLLIHTGTAADDNHFQ-----QAMWYTEDGIASTAHOHIYTMHF 733

Qy 733 IKQCFSLP 740
 Db 732 IKQCFSLP 739

Search Completed: February 17, 2006, 20:41:02
 Job time: 200 sec_S

Db	39	SRKTYTIDYLNTYRKLYSRWTISHELYKQENNLVNAEYCNSSPLENSTPDEF	98	PP 19-AUG-1993; XX	93WO-US007923.
Oy	73	GHSINDYISIISPQGPFILENTYKQHNSHTTASYDIDLNRQLITERIPNTNTQWTWS	132	PR 21-AUG-1992; XX	92US-00934162.
Db	99	GHSINDYISIISPQGPFILENTYKQHNSHTTASYDIDLNRQLITERIPNTNTQWTWS	158	(DAND) DANA FARBER CANCER INST INC.	
Oy	133	PVGHKLAYWNNIDYKIEPNLPSYRITWTGKEDITYNGITDWWYEEVPSAYSALMWSP	192	PI Morimoto C, Schlossman S, Tanaka T;	
Db	159	PVGHKLAYWNNIDYKIEPNLPSYRITWTGKEDITYNGITDWWYEEVPSAYSALMWSP	218	XX DR; 1994-151317/18.	
Oy	193	NGTFLAYAQFNDEPVPLIEPSYPSDESQYPKTVRVPKAGAVNPYKPFVNTDSLSS	252	XX DR-N-PSDB; AAQ63261.	
Db	219	NGTFLAYAQFNDEPVPLIEPSYPSDESQYPKTVRVPKAGAVNPYKPFVNTDSLSS	278	XX PT useful for stimulating immune response, e.g. for treatment of AIDS to counteract immunosuppressive drug, and as vaccine adjuvant.	
Oy	253	VTNATSOITAPASMLGHDYLCDVTWATQRISLQMLRQNYSYMIDCYDESSGRWN	312	XX Disclosure; Page 46-49; 85pp; English.	
Db	279	VTNATSOITAPASMLGHDYLCDVTWATQRISLQMLRQNYSYMIDCYDESSGRWN	338	XX	
Oy	313	CLVARQHIEMSTTGWGRFRPSBPFHLDGNSFYKLTNSNEGYRHICYFQIDKQDCTFIT	372	CC This sequence represents the human T cell activation antigen CD26. The invention is concerned with polypeptide fragments and analogues of CD26 which have internal deletions (see also AARS-4612-14). The analogues pref.	
Db	339	CLVARQHIEMSTTGWGRFRPSBPFHLDGNSFYKLTNSNEGYRHICYFQIDKQDCTFIT	398	CC lack residues 3-9 or 24-34. These analogues are soluble under physiological conditions and lack enough amino acid residues to render them susceptible to cleavage by signal peptidase. The peptide fragments and analogues useful as immune or response- stimulating therapeutics, e.g. they may be used for treatment of disease conditions characterised by immunosuppression, e.g. AIDS or AIDS-related complex, other virally or environmentally-induced conditions, and certain congenital immune deficiencies. The peptides can be employed to increase immune function which has been impaired by use of immunosuppressive drugs, such as certain chemotherapeutic drugs. (Updated on 25-MAR-2003 to correct PN Field.)	
Oy	373	KGTWEVIGBALTSDFLYIISNEYKMPGGRNLYKIQLSDYTKTCLSCLENPERQYYS	432	XX Sequence 766 AA;	
Db	399	KGTWEVIGBALTSDFLYIISNEYKMPGGRNLYKIQLSDYTKTCLSCLENPERQYYS	458	XX	
Oy	433	VSPFSKEAKYQYLRCSEGPGLPLYLSSNDKGRLVLDNSALDKRLQVNPOMPSKELDFII	492	Query Match Score 3928; DB 2; Length 766;	
Db	459	VSPFSKEAKYQYLRCSEGPGLPLYLSSNDKGRLVLDNSALDKRLQVNPOMPSKELDFII	518	Best Local Similarity 99.9%; Pred. No. 0;	
Oy	493	LNETKFWYQMLLPHEFDKSKYKPLIUDVYAGPCSKQDADTVFRLWATYLASTENIIVASP	552	Matches 72/7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
Db	519	LNETKFWYQMLLPHEFDKSKYKPLIUDVYAGPCSKQDADTVFRLWATYLASTENIIVASP	578	Query 13 SRKTYTIDYLNTYRKLYSRWTISHELYKQENNLVNAEYCNSSPLENSTPDEF	
Oy	553	DGRGSGYQGDKIMHAINRRLGTFEYDQTEARQFSKMGFVDNKRIAIWGWSYGGYVTSM	612	Db 39 SRKTYTIDYLNTYRKLYSRWTISHELYKQENNLVNAEYCNSSPLENSTPDEF	
Db	579	DGRGSGYQGDKIMHAINRRLGTFEYDQTEARQFSKMGFVDNKRIAIWGWSYGGYVTSM	638	Qy 73 GH51NDYISSPDGQFILLYNNYKQWRHSYTASYDIDLNRQLITEERIPNTNTQWTWS	
Oy	613	VLGSGSGVFKCGIAVAPVSRMEYYSVTGYMLPTEDNLDHNTNTMSRAENFKQV	672	Db 99 GH51NDYISSPDGQFILLYNNYKQWRHSYTASYDIDLNRQLITEERIPNTNTQWTWS	
Db	639	VLGSGSGVFKCGIAVAPVSRMEYYSVTGYMLPTEDNLDHNTNTMSRAENFKQV	698	Qy 133 PVGHKLAYWNNIDYKIEPNLPSYRITWTGKEDITYNGITDWWYEEVPSAYSALMWSP	
Oy	673	BYLLIHTGATTDDNVRHQOSAQIQLSKALVDVGFDQAMWYTDSDHGTASSTAHQIYTHMSHF	732	Db 159 PVGHKLAYWNNIDYKIEPNLPSYRITWTGKEDITYNGITDWWYEEVPSAYSALMWSP	
Db	699	BYLLIHTGATTDDNVRHQOSAQIQLSKALVDVGFDQAMWYTDSDHGTASSTAHQIYTHMSHF	758	Qy 193 NGTFLAYAQFNDEPVPLIYSFYDESLQYPTKTRVYKAGANPVTKFVNTDSLSS	
Oy	733	IKQCFSLP 740		Db 219 NGTFLAYAQFNDEPVPLIYSFYDESLQYPTKTRVYKAGANPVTKFVNTDSLSS	
Db	759	IKQCFSLP 766		Qy 253 VTNATSOITAPASMLGHDYLCDVTWATQRISLQMLRQNYSYMIDCYDESSGRWN	
RESULT 32					
AR54611					
ID	AARS4611	standard; protein: 766 AA.			
XX					
AC	AARS4611;				
XX					
DT	25-MAR-2003 (revised)				
XX					
DT	09-DEC-1994 (first entry)				
XX					
DE	Native	CD26.			
XX					
KW	Human; T cell activation antigen; CD26; analogues; deletion; soluble;				
KW	signal peptidase; immune-stimulating; response-stimulating; AIDS;				
KW	immunosuppression; AIDS-related complex.				
XX					
OS	Homo sapiens.				
XX					
PN	WO9409132-A1.				
XX					
PD	28-APR-1994.				
XX					
Qy	493 LNETKFWYQMLLPHEFDSSKCYPLLDVYAGPCSKQADTVFRLWATYLASTENIIVASF	552			
Db	519 LNETKFWYQMLLPHEFDSSKCYPLLDVYAGPCSKQADTVFRLWATYLASTENIIVASF	578			

PF	08-JAN-2004; 2004WO-US000368.	Db	519 LNETKEWYQMLPPFDKSKYKPLILDVAGPCSSQKADIVFRLNWATYLASTENIIVASF 578
PR	08-JAN-2003; 2003US-0438735P.	Qy	553 DGRGSGYQGDKIMMHAINRRLGTFEYBDQLEAAROSKMGFVDNKRKIAWNSYGGVVTSM 612
PA	(BRIM) BRISTOL-MYERS SQUIBB CO.	Db	579 DGRGSGYQGDKIMMHAINRRLGTFEYBDQLEAAROSKMGFVDNKRKIAWNSYGGVVTSM 638
XX		Qy	613 VLGSQSGVFKCGIAVAPVSRMEYDVSYTERYMGILTPEDNLDHYRNSTMRSRAENFKQV 672
PI	Amler LC, Januario T;	Db	639 VLGSQSGVFKCGIAVAPVSRWEYDVSYTERYMGILTPEDNLDHYRNSTMRSRAENFKQV 698
XX	WPI; 2004-544114/52.	Qy	673 BYLLHGTAADNVHFOQSAQISKALVDGVGDFQAMWYTDHDGIASSTAQHIIYTHMSHF 732
DR	DR-N-PSDB, ADQ80241.	Db	699 BYLLHGTAADNVHFOQSAQISKALVDGVGDFQAMWYTDHDGIASSTAQHIIYTHMSHF 758
XX	Identifying a mammal that will respond therapeutically to a method of treating cancer comprises comparing the level of a biomarker in a mammal before and after exposure to an epidermal growth factor receptor (EGFR) modulator.	Qy	733 IKQCFSLP 740
PS	Disclosure; SEQ ID NO 137; 520pp; English.	Db	759 IKQCFSLP 766
PS		RESULT 31	
XX		AEB77579	standard; protein; 766 AA.
CC	The invention relates to a method of identifying a mammal that will respond therapeutically to a method of treating cancer by administering an epidermal growth factor receptor (EGFR) modulator by comparing the level of a biomarker in a mammal before and after exposure to an EGFR modulator. The method comprises: (a) measuring, in the mammal, the level of at least one biomarker identified in the specification; (b) exposing the mammal to the EGFR modulator; and (c) measuring in the mammal the level of the biomarker, where a difference in the level in step (c) compared to step (a) indicates that the mammal will respond therapeutically to the method of treating cancer. The method and biomarkers are useful for identifying a mammal that will respond therapeutically to a method of treating cancer by administering an epidermal growth factor receptor (EGFR) modulator. This sequence corresponds to one of the biomarkers whose levels of expression is measured in the method of the invention.	XX	AC AEB77579;
CC	Sequence 766 AA;	XX	XX DT 06-OCT-2005 (first entity)
CC	Score 3929; DB 8; Length 766;	XX	XX DE Human dipeptidyl peptidase IV enzyme - SEQ ID 1.
CC	Best Local Similarity 99.7%; Pred. No. 0; Mismatches 1; Indels 0; Gaps 0;	XX	XX DE Human dipeptidyl peptidase IV enzyme - SEQ ID 1.
CC	Matches 726; Conservative 1; Mismatches 1; Indels 0; Gaps 0;	XX	XX DE Human dipeptidyl peptidase IV enzyme - SEQ ID 1.
Qy	13 SRKTYLTIDYLKNTYRLKLYSLRWSIDHLYLQKQENNLIVLNAEYGNSSVPLLENSTFDEF 72	XX	XX PR 03-FEB-2004; 2004US-00770712.
Db	39 SRKTYLTIDYLKNTYRLKLYSLRWSIDHLYLQKQENNLIVLNAEYGNSSVPLLENSTFDEF 98	XX	XX PA (VOJD/) VOJDANI A.
Qy	73 GHSINDYSISPQGQFILLYEYNTVKQWHDHISYTAQDYLNRQLITEERIPNNNTQWTS 132	XX	XX PI Vojdani A;
Db	99 GHSINDYSISPQGQFILLYEYNTVKQWHDHISYTAQDYLNRQLITEERIPNNNTQWTS 158	XX	XX DR WPI; 2005-562713/57.
Qy	133 PVGHKLAYVWWNDIYVKEEPNLPYSRITWKGEDIYNGITDWMVYBEEVFSAYSALWNSP 192	XX	XX XX Disclosure; SEQ ID NO 1; 89pp; English.
Db	159 PVGHKLAYVWWNDIYVKEEPNLPYSRITWKGEDIYNGITDWMVYBEEVFSAYSALWNSP 218	XX	XX PT Determining etiology of autistic spectrum disorder in patient, by determining level of infectious agent/toxic chemical/dietary protein derived antigen in samples of patient, comparing it with normal level of PT derived antigen in samples of patient, comparing it with normal level of PT antigens of control subjects.
Qy	193 NGTFLAYAQENDTEVPLIYEYPSYDSLSQYPKTVRYPKAGAVNPYTVKFPVNTDSLSS 252	XX	XX CC The invention comprises a method of determining etiology of an autistic spectrum disorder in a patient. The method involves determining the level CC of an infectious agent, toxic chemical, or dietary protein derived CC antigen, or their antibodies in samples of patient, and comparing CC antigens/antibodies levels with normal levels of antigens/antibodies from CC control subjects. The method of the invention is useful for determining CC the etiology of an autistic spectrum disorder, such as autism, pervasive CC development disorder and Asperger's syndrome, the present amino acid CC sequence represents a human dipeptidyl peptidase IV enzyme that was used CC in the exemplification of the invention.
Db	219 NGTFLAYAQENDTEVPLIYEYPSYDSLSQYPKTVRYPKAGAVNPYTVKFPVNTDSLSS 278	XX	XX SQ Sequence 766 AA;
Qy	253 VTNATSIQITAPASMLIGDYLQDVTATQBLISLWLRRLQYNSWIDICDYEDESGRN 312	XX	XX SQ Query Match 97.7%; Score 3929; DB 9; Length 766;
Db	279 VTNATSIQITAPASMLIGDYLQDVTATQBLISLWLRRLQYNSWIDICDYEDESGRN 338	XX	XX Best Local Similarity 99.7%; Pred. No. 0; Matches 726; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy	313 CLVARQHTEMSTGWRFRSPSEPHFTLGDNSFYKLTISNEGYRHICYFQIDKDKCTFIT 372	XX	XX
Db	339 CLVARQHTEMSTGWRFRSPSEPHFTLGDNSFYKLTISNEGYRHICYFQIDKDKCTFIT 398	XX	XX
Qy	373 KGTWEVIGIEALTSQDLYYISNBVKGMPPGRMLYKIQSLSDYTKVTCLSCELNPEROYCS 432	XX	XX
Db	399 KGTWEVIGIEALTSQDLYYISNBVKGMPPGRMLYKIQSLSDYTKVTCLSCELNPEROYCS 458	XX	XX
Qy	433 VSFSEKEAKYYQRCGSPOLPLVTLHSSVNDKGLRLEEDNSALDKMIVQVNSPSKULDFI 492	XX	XX
Db	459 VSFSEKEAKYYQRCGSPOLPLVTLHSSVNDKGLRLEEDNSALDKMIVQVNSPSKULDFI 518	XX	XX
Qy	493 LNETKEWYQMLLPHFDSKCKYPLLDDVYAGPCSQKADTVFRLNWATYLASTENIIVASF 552	XX	XX
		Qy	13 SRKTYLTIDYLKNTYRLKLYSLRWSIDHLYLQWVABXGNSSVFLENSTFDEF 72

Qy 673 YLLINGTADDNVHFQQAQISKALVDGVDFQAMYTDEDHGIASTAHQIYTHMSHF 732
 Db 699 YLLINGTADDNVHFQQAQISKALVDGVDFQAMYTDEDHGIASTAHQIYTHMSHF 758

Qy 733 IKQCPSP 740
 Db 759 IKQCPSP 766

RESULT 29
 ABP55629 standard; protein; 766 AA.
 AC ABP55629;
 XX DT 20-PEP-2003 (first entry)
 XX DE Human dpp4 protein sequence.
 XX DPP10; dipeptidyl peptidase; prolyl oligopeptidase; enzyme; asthma;
 KW antiinflammatory; antiasthmatic; antipsoriatic; antiarthritic;
 KW antirheumatic; vaccine; gene therapy; inflammatory disease;
 KW inflammatory bowel disease; atopy; rheumatoid arthritis; psoriasis;
 KW chromosome 2q14.
 XX OS Homo sapiens.
 XX PN WO200286113-A2.
 XX PD 31-OCT-2002.
 XX PF 24-APR-2002; 2002WO-GB001887.
 XX PR 24-APR-2001; 2001GB-0001044.
 XX PR 24-APR-2001; 2001GB-0001046.
 XX PR 12-OCT-2001; 2001GB-00024575.
 XX PR 12-OCT-2001; 2001GB-00024594.
 XX PA (ISIS-) ISIS INNOVATIONS LTD.
 XX Cookeon WOCM, Moffat MF, Allen M, Lench N;
 XX DR WPI; 2003-093132/08.
 XX PT New nucleic acid sequence comprising DPPI0 mRNA, useful for the
 PT manufacture of a medicament for regulating DPPI0 protein expression or
 PT for preventing or treating inflammatory disease e.g., inflammatory bowel
 PT disease.
 XX PS Example 2; Fig 23; 321PP; English.
 XX The present invention describes a new isolated nucleic acid sequence (I)
 CC comprising a DPPI0 mRNA sequence. DPPI0 is a dipeptidyl peptidase (also
 CC known as prolyl oligopeptidase). (I) has antiinflammatory, antiasthmatic,
 CC anti-psoriatic, antiarthritic and antirheumatic activities, and can be
 CC used in vaccines and gene therapy. A composition comprising (I) can be
 CC used for the manufacture of a medicament for regulating DPPI0 expression
 CC or for preventing or treating inflammatory disease e.g., inflammatory
 CC bowel disease, asthma, atopy, rheumatoid arthritis or psoriasis. (I) can
 CC also be used in an assay for detecting or measuring DPPI0 in a sample. A
 CC host cell comprising (I) can be used for producing recombinant DPPI0 gene
 CC products, or in drug screening systems to identify agents for diagnosis
 CC or treatment of individuals having or susceptible to inflammatory
 CC disease. Human DPPI0 is located on chromosome 2, more specifically
 CC chromosome 2q14. ABP84254 to ABQ8461 to ABP5569 to ABP55629 represent
 CC sequences used in the exemplification of the present invention
 XX Sequence 766 AA;

Qy 13 SRKTYLTDLKNTYRKLYSLRNTSDHEYLYKQENNLVYNAYGNNSYFLENSTFDEF 72
 Db 39 SRKTYLTDLKNTYRKLYSLRNTSDHEYLYKQENNLVYNAYGNNSYFLENSTFDEF 98

Qy 73 GHSHINDYS1SPDGQFILLEYNNVYKQWRHSTASYDYLINKROLITEERIPNNTQVNTWS 132
 Db 99 GHSHINDYS1SPDGQFILLEYNNVYKQWRHSTASYDYLINKROLITEERIPNNTQVNTWS 158

Qy 133 PVGHKLAYWNNDIVKIEPNLPSRITWKGEDIYNGTDTWYEEVSAYSALWWSP 192
 Db 219 NGTFLAYAQNDTEVPLIESFSYSDLSQPKTIVPYPKAGANPTVKFVVNTDSLSS 278

Qy 159 PVGHKLAYWNNDIVKIEPNLPSRITWKGEDIYNGTDTWYEEVSAYSALWWSP 218

Qy 193 NGTFLAYAQNDTEVPLIESFSYSDLSQPKTIVPYPKAGANPTVKFVVNTDSLSS 252

Db 253 VTNATSIQITAPASMLIGDHYLCVWTATOBRIISQWLRIQNTSYMDICDYZESSGRWN 312

Db 279 VTNATSIQITAPASMLIGDHYLCVWTATOBRIISQWLRIQNTSYMDICDYZESSGRWN 338

Qy 313 CLVAQHIEINSTGIVGRFPSEPEHTLQNSFVIIISNEGYRHICYQIDKQDCTPIT 372

Db 339 CLVAQHIEINSTGIVGRFPSEPEHTLQNSFVIIISNEGYRHICYQIDKQDCTPIT 398

Qy 373 RGTMEVIGITALSDYLYTISNEYKGMPGGRNLXLYKIQLSDYTKTCLSCLEINPERCQYYS 432

Db 399 KGTWEVIGITALSDYLYTISNEYKGMPGGRNLXLYKIQLSDYTKTCLSCLEINPERCQYYS 458

Qy 433 VSPSKEAKTYQLRCSPGPGLPLYTLHSSYNDKGFLRVLDENSALDQMLQNYQMPSKXLLDFII 492

Db 459 VSPSKEAKTYQLRCSPGPGLPLYTLHSSYNDKGFLRVLDENSALDQMLQNYQMPSKXLLDFII 518

Qy 493 LNEFKWYQMLPHEFDKSKYKPYLIDVAGPCQKADTVPLRNLWATYLASTENIVASF 552

Db 519 LNEFKWYQMLPHEFDKSKYKPYLIDVAGPCQKADTVPLRNLWATYLASTENIVASF 578

Qy 553 DGRGSGYQGDQDKIMHAIRRLGTPEVDEDQLEAAQFSKMGFVDRNTRIAINGWYSGYVTSM 612

Db 579 DGRGSGYQGDQDKIMHAIRRLGTPEVDEDQLEAAQFSKMGFVDRNTRIAINGWYSGYVTSM 638

Qy 613 VLGGSGSGYPKCGIAYAPVSRWEYDSVYTERMGLPTPEDNLHYRNSTMRSRAENFKQV 672

Db 639 VLGGSGSGYPKCGIAYAPVSRWEYDSVYTERMGLPTPEDNLHYRNSTMRSRAENFKQV 698

Qy 673 EYLJLHGADDNVFQQSAQISKALVDVGYDFQAMWYTEDHGIASSTAHQIYTHMSHF 732

Db 699 EYLJLHGADDNVFQQSAQISKALVDVGYDFQAMWYTEDHGIASSTAHQIYTHMSHF 758

Qy 733 IKQCPSLP 740

Db 759 IKQCPSLP 766

RESULT 30
 ID ADQ80365 standard; Protein; 766 AA.
 AC ADQ80365;
 XX DT 21-OCT-2004 (first entry)
 DE Dipeptidylpeptidase IV protein.
 XX KW cytostatic; epidermal growth factor receptor modulator; identification;
 KW therapeutic response; cancer; EGFR; biomarker.
 XX Homo sapiens.
 XX PN WO004063709-A2.
 XX PD 29-JUL-2004.

Query Match 97.7%; Score 3929; DB 6; Length 766;
 Best Local Similarity 99.7%; Pred. No. 0;
 Matches 726; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db	219	NGTFLAYAQFNDTEVPLTEYSFSDESLQYPKTVRVPYKAGAVNPTVKFFVVNTDSLSS	278	XX	WPI; 2004-420057/39.
Qy	253	VTNATSIQITAPASMLIGDHYLCDVTTWATQERISLQMRRIONYSYMIDICDYDESSGRWN	312	DR	N-PSDB; AD019339.
Db	279	VTNATSIQITAPASMLIGDHYLCDVTTWATQERISLQMRRIONYSYMIDICDYDESSGRWN	338	XX	Novel PRO polypeptide e.g., PRO69614, PRO71106, or PRO86388 useful for treating an immune related disorder such as systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis or spondyloarthritis.
Qy	313	CLVARQHTEMSTGWRGRPRSEPHFTDGLNSFYKLTISNEEYRHICFQIDKKOCTFIT	372	PT	PT
Db	339	CLVARQHTEMSTGWRGRPRSEPHFTDGLNSFYKLTISNEEYRHICFQIDKKOCTFIT	398	PT	PT
Qy	373	KGTWEVIGTEALTSIDLIVYISNEYKGMPGGRNLYKIQLDTIVKTCUCLSCELNPERCQYS	432	XX	Claim 7: SEQ ID NO 330: 1731PP; English.
Db	399	KGTWEVIGTEALTSIDLIVYISNEYKGMPGGRNLYKIQLDTIVKTCUCLSCELNPERCQYS	458	PS	The invention relates to human PRO polypeptides and the polynucleotides encoding them. The polypeptides and polynucleotides are useful for treating and diagnosing immune related disorders in mammals. The immune related disorders include systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, systemic sclerosis, Sjogren's syndrome, vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, demyelinating diseases of the central or peripheral nervous system, demyelinating polyneuropathy, Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. This sequence represents a human PRO polypeptide of the invention.
Qy	433	VFSKKEAKXYQYQLRCSGRLPPLTHSSVNDKSLRVLIEDNSALDKMQLNQVNSKPKLDFII	492	CC	CC
Db	459	VFSKKEAKXYQYQLRCSGRLPPLTHSSVNDKSLRVLIEDNSALDKMQLNQVNSKPKLDFII	518	CC	CC
Qy	493	LNBTKFVNQMLIPPHEDSKKRYKPLLLDLYAGRCQSOKADTVERPLNWATYLASTENIIVASP	552	CC	CC
Db	519	LNBTKFVNQMLIPPHEDSKKRYKPLLLDLYAGRCQSOKADTVERPLNWATYLASTENIIVASP	578	CC	CC
Qy	553	DGRGSGYQGDKIMHAIRNRLGTFEVEDQIEARQFSKMGFVDNKRKIAWGMNSGGVTSM	612	CC	CC
Db	579	DGRGSGYQGDKIMHAIRNRLGTFEVEDQIEARQFSKMGFVDNKRKIAWGMNSGGVTSM	638	CC	CC
Qy	613	VLGSGSGVYQKFCGTAVAPVSRWEYDSYSTERTMGLPTPEDNDHYTNSTMNSRAENFKQV	672	XX	Sequence 766 AA;
Db	639	VLGSGSGVYQKFCGTAVAPVSRWEYDSYSTERTMGLPTPEDNDHYTNSTMNSRAENFKQV	698	XX	Query Match 97.0%; Score 3933; DB 8; Length 766;
Qy	673	EVILHGTADDNTHFOQSQIQLSKALVQDQAMWYDDEDGIASTAHQHITYMHSF	732	Qy	Best Local Similarity 99.9%; Pred. No. 0;
Db	699	EVILHGTADDNTHFOQSQIQLSKALVQDQAMWYDDEDGIASTAHQHITYMHSF	758	Db	Matches 727; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy	733	IKQCFSLP	740	Qy	13 SRKTYTLDYKNTLKRNTYKLYSLRWSIDHELYKQENNLIVFNAEYKGNSVPLNSTFDEF 72
Db	759	IKQCFSLP	766	Db	39 SRKTYTLDYKNTLKRNTYKLYSLRWSIDHELYKQENNLIVFNAEYKGNSVPLNSTFDEF 98
Qy	773	NGTFLAYAQFNDTEVPLIEYSFSDESLQYPKTVRVPYKAGAVNPTVKFFVVNTDSLSS	252	Qy	73 GHSINDYNSISPDGOFILLEYNNVKQWKRHSYTASYDIDYDLNRQLTTEERIPNNTWVTS 132
Db	799	NGTFLAYAQFNDTEVPLIEYSFSDESLQYPKTVRVPYKAGAVNPTVKFFVVNTDSLSS	278	Db	99 GHSINDYNSISPDGQPTILENNVKQWKRHSYTASYDIDYDLNRQLTTEERIPNNTWVTS 158
Qy	813	PVGHKLAYVWNNDIYKIEPNLPSRITWTGKEDIYNGITDWWYEEEVFSAYSALWWSWP	192	Qy	1.33 PVGHKLAYVWNNDIYKIEPNLPSRITWTGKEDIYNGITDWWYEEEVFSAYSALWWSWP 192
Db	839	PVGHKLAYVWNNDIYKIEPNLPSRITWTGKEDIYNGITDWWYEEEVFSAYSALWWSWP	218	Db	159 PVGHKLAYVWNNDIYKIEPNLPSRITWTGKEDIYNGITDWWYEEEVFSAYSALWWSWP 218
Qy	853	VTNATSIQITAPASMLIGDHYLCDVTTWATQERISLQMRRIONYSYMIDICDYDESSGRWN	312	Qy	1.93 NGTFLAYAQFNDTEVPLIEYSFSDESLQYPKTVRVPYKAGAVNPTVKFFVVNTDSLSS
Db	879	VTNATSIQITAPASMLIGDHYLCDVTTWATQERISLQMRRIONYSYMIDICDYDESSGRWN	338	Db	219 NGTFLAYAQFNDTEVPLIEYSFSDESLQYPKTVRVPYKAGAVNPTVKFFVVNTDSLSS
Qy	903	CLVARQHIEMTGWRGRPRSEPHFTDGLNSFYKLTISNEEYRHICFQIDKKOCTFIT	372	Qy	253 VTNATSIQITAPASMLIGDHYLCDVTTWATQERISLQMRRIONYSYMIDICDYDESSGRWN
Db	929	CLVARQHIEMTGWRGRPRSEPHFTDGLNSFYKLTISNEEYRHICFQIDKKOCTFIT	398	Db	279 VTNATSIQITAPASMLIGDHYLCDVTTWATQERISLQMRRIONYSYMIDICDYDESSGRWN
Qy	933	KGTWEVIGTEALTSIDLIVYISNEYKGMPGRNLYKQLSDTIVKTCUCLSCBNPERCQYS	432	Qy	313 CLVARQHIEMTGWRGRPRSEPHFTDGLNSFYKLTISNEEYRHICFQIDKKOCTFIT 372
Db	959	KGTWEVIGTEALTSIDLIVYISNEYKGMPGRNLYKQLSDTIVKTCUCLSCBNPERCQYS	458	Db	339 CLVARQHIEMTGWRGRPRSEPHFTDGLNSFYKLTISNEEYRHICFQIDKKOCTFIT 398
Qy	973	VSFSKEAKYQYQLRCSGFLPLTLLHSSVNDKGLRVLEDNSALDKMQLNQVNSKPKLDFII	492	Qy	373 KGTWEVIGTEALTSIDLIVYISNEYKGMPGRNLYKQLSDTIVKTCUCLSCBNPERCQYS
Db	993	VSFSKEAKYQYQLRCSGFLPLTLLHSSVNDKGLRVLEDNSALDKMQLNQVNSKPKLDFII	518	Db	399 KGTWEVIGTEALTSIDLIVYISNEYKGMPGRNLYKQLSDTIVKTCUCLSCBNPERCQYS
Qy	1013	LNETKFWYQMLIPPHDKSKKRYPLLLDLYAGPCSKQADTVPLNATYLASTENIIVASP	552	Qy	433 VSFSKEAKYQYQLRCSGFLPLTLLHSSVNDKGLRVLEDNSALDKMQLNQVNSKPKLDFII
Db	1039	LNETKFWYQMLIPPHDKSKKRYPLLLDLYAGPCSKQADTVPLNATYLASTENIIVASP	578	Db	459 VSFSKEAKYQYQLRCSGFLPLTLLHSSVNDKGLRVLEDNSALDKMQLNQVNSKPKLDFII
Qy	1053	DGRGSGYQGDKIMHAIRNRLGTFEVEDQIEARQFSKMGFVDNKRKIAWGMNSGGVTSM	612	Qy	493 LNEMTKFWYQMLIPPHDKSKKRYPLLLDLYAGPCSKQADTVPLNATYLASTENIIVASP
Db	1079	DGRGSGYQGDKIMHAIRNRLGTFEVEDQIEARQFSKMGFVDNKRKIAWGMNSGGVTSM	638	Db	519 LNETKFWYQMLIPPHDKSKKRYPLLLDLYAGPCSKQADTVPLNATYLASTENIIVASP
PA	1093	(GETH) GENENTECH INC.		PA	553 DGRGSGYQGDKIMHAIRNRLGTFEVEDQIEARQFSKMGFVDNKRKIAWGMNSGGVTSM
XX	1113	VLGSGSGVYFKCGIAVAPVSRWEYDSVTERYMGFLPTPEDNDHYRNSTMRAENFKQV	672	XX	613 VLGSGSGVYFKCGIAVAPVSRWEYDSVTERYMGFLPTPEDNDHYRNSTMRAENFKQV
PI	1139	VLGSGSGVYFKCGIAVAPVSRWEYDSVTERYMGFLPTPEDNDHYRNSTMRAENFKQV	698	PI	639 VLGSGSGVYFKCGIAVAPVSRWEYDSVTERYMGFLPTPEDNDHYRNSTMRAENFKQV

73 GHSINDYSISPPGQFILENTYVKONHSYTASYDIDLNRQLITERIPNNTOWTWS 132
 99 GHSINDYSISPPGQFILENTYVKONHSYTASYDIDLNRQLITERIPNNTOWTWS 158
 PR 13-NOV-2002; 2002W0-US036810.
 XX
 PR 13-NOV-2001; 2001US-0350666P.
 PR 21-NOV-2001; 2001US-0332464P.
 PR 29-NOV-2001; 2001US-0334393P.
 PR 03-DEC-2001; 2001US-0335394P.
 PR 14-DEC-2001; 2001US-0340376P.
 PR 08-JAN-2002; 2002US-0341211P.
 PR 10-JAN-2002; 2002US-0341349P.
 PR 08-FEB-2002; 2002US-035250P.
 PR 13-FEB-2002; 2002US-03555714P.
 PR 20-FEB-2002; 2002US-0359775P.
 PR 29-MAR-2002; 2002US-0366809P.
 PR 04-APR-2002; 2002US-0370110P.
 PR 12-AFR-2002; 2002US-037246P.
 PR 05-JUN-2002; 2002US-0386614P.
 PR 16-JUL-2002; 2002US-0386839P.
 PR 22-JUL-2002; 2002US-039775P.
 PR 22-SEP-2002; 2002US-0397845P.
 PR 09-SEP-2002; 2002US-0409450P.
 XX (EOSH-) EOS BIOTECHNOLOGY INC.
 PA
 XX
 PA Afar D, Aziz N, Ginsburg WM, Glynne RC, Hevezi PA;
 Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;
 XX WPI: 2003-468549/44.
 DR N-PSDB; ADN39603.

313 CLVARQHIEEMSTGWRGRFRPSBPHTLQDGNSFYKLIISNEEGYRHYCIFQIDKDDCTFIT 372
 339 CLVARQHIEEMSTGWRGRFRPSBPHTLQDGNSFYKLIISNEEGYRHYCIFQIDKDDCTFIT 398
 PR Determining the presence or absence of a pathological cell in a patient, useful for diagnosing, prognosing or treating cancer. comprises detecting a nucleic acid in a biological sample.

373 KGTWEVIGEALTSQYIISNEYKMPGRNLKYLQDSDYTKVTCIQLSCELNPERQYYS 432
 399 KGTWEVIGEALTSQYIISNEYKMPGRNLKYLQDSDYTKVTCIQLSCELNPERQYYS 458
 PR Claim 12; SEQ ID NO A204; 1385pp; English.
 XX
 PR The invention relates to nucleic acids and proteins (ADN38683-ADN40064) whose expression is upregulated or downregulated in specific cancers or other diseases such as angiogenic or fibrotic disorders, and to methods of determining the presence or absence of a pathological cell in a patient by detecting a nucleic acid at least 80% identical to those of the invention or by detecting a polypeptide of the invention. The invention also relates to expression vectors and host cells comprising a nucleic acid of the invention; antibodies which specifically bind a polypeptide of the invention; use of such antibodies for drug targeting; and methods of screening for modulators of activity or expression of the polypeptides and nucleic acids. The nucleic acids, polypeptides, antibodies and methods are useful for diagnosing, prognosing and treating cancer and other conditions such as psoriasis, ischaemia, heart disease, atherosclerosis, inflammatory diseases, autoimmune diseases, retinal neovascularisation syndrome, scarring and uterine fibroids. They may also be useful in wound healing and in contraception. The present sequence represents a polypeptide of the invention.

493 LNETKTYQMLPPHDPSKSKYPLDYYAGPCSKQADTVFRLWATYLASTENIVASP 552
 519 LNETKTYQMLPPHDPSKSKYPLDYYAGPCSKQADTVFRLWATYLASTENIVASP 578
 PR Sequence 766 AA;

553 DGRGSGYQGDKIMHA.NRRLGTFEVDQIEAROFSKMGFDNKRPIAINGMSYGGYVSM 612
 579 DGRGSGYQGDKIMHA.NRRLGTFEVDQIEAROFSKMGFDNKRPIAINGMSYGGYVSM 638
 PR Query Match 97.8%; Score 3913; DB 7; Length 766;
 PR Best Local Similarity 99.9%; Pred. No. 0;
 PR DE 0; Mismatches 0; Indels 0; Gaps 0;
 PR Matches 727; Conservative 0;
 PR
 PR 13 SRKTYTLDYKTYTRKLKYSRMLSDHELYKQENNLVENARYGNSVFLNSTDEF 72
 PR 39 SRKTYTLDYKTYTRKLKYSRMLSDHELYKQENNLVENARYGNSVFLNSTDEF 98
 PR 73 GHSINDYSISPPGQFILENTYVKONHSYTASYDIDLNRQLITERIPNNTOWTWS 132
 PR 99 GHSINDYSISPPGQFILENTYVKONHSYTASYDIDLNRQLITERIPNNTOWTWS 158
 PR 133 PVGHKLAYWNNDIYVKLIEPNLPRYITWKGKEDILYNGITDNYVEEVSAYSAWMNSP 192
 PR 159 PVGHKLAYWNNDIYVKLIEPNLPRYITWKGKEDILYNGITDNYVEEVSAYSAWMNSP 218
 PR 22-MAY-2003.

RESULT 27
 ADN39604
 ID ADN39604 standard; protein; 766 AA.
 XX
 AC ADN39604;
 XX
 DT 17-JUN-2004 (first entry)
 XX Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:A204.
 XX Human; differential expression; cancer; angiogenic disorder;
 KW fibrotic disorder; psoriasis; ischaemia; heart disease;
 KW inflammatory disease; autoimmune disease;
 KW retinal neovascularisation syndrome; scarring; uterine fibroid;
 KW detection; diagnosis; prognosis; drug screening; drug targeting;
 KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;
 KW vulnerability; gene therapy; vaccine.
 OS Homo sapiens.
 XX
 PR WO2003042661-A2.
 XX
 PR 22-MAY-2003.

CC antidiabetic, hypotensive, nephrotropic, antiarthritic and
 CC antiinflammatory activities, and can be used in gene therapy. (M1) is
 CC useful in targeting pharmaceuticals or other therapeutics to specific
 CC tissues using tissue-specific endothelial membrane proteins. A
 CC therapeutic complex may be used to treat or diagnose any disease for
 CC which a tissue- or organ-specific treatment would be efficacious, such as
 CC in cases of infections (e.g., bacterial, viral, fungal and parasitic),
 CC epilepsy, schizophrenia, cancer, Parkinson's disease, Alzheimer's
 CC disease, asthma, diabetes, hypertension, polycystic kidney disease,
 CC arthritis and inflammatory bowel disease. The present sequence
 CC represents a human liver dipeptidyl peptidase IV (DPP4), which is used in
 CC an example from the present invention.

xx Sequence 766 AA;

Query	Match	Score 97.8†; Best Local Similarity 99.9†; Pred. No. 0; Matches 727; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db	13 SRKTYTITDYLKNTYRKLYSLRWISHEYLKQENNLIVVNAEYGNSSVPLENSFDEF 72	xx
Db	39 SRKTYTITDYLKNTYRKLYSLRWISHEYLKQENNLIVVNAEYGNSSVPLENSFDEF 98	xx
Qy	73 GHSINDYSISPDQFQFILEYNTVKQWHSYTASYDIDLNQQLITERIPNNTQWVTS 132	xx
Db	99 GHSINDYSISPDQFQFILEYNTVKQWHSYTASYDIDLNQQLITERIPNNTQWVTS 158	xx
Qy	133 PVGHKLLAYVWNNDIYVKEIPEPNPSYRTRTWGKEDILYNGGITDWWYBEBVFSAYSALWWSP 192	xx
Db	159 PVGHKLLAYVWNNDIYVKEIPEPNPSYRTRWGTBEBVFSAYSALWWSP 218	xx
Qy	193 NGTFLAYQFNQDTEVPLIEYSPYSDESLQYKPTVRYPKAGAVNPTVKKFVVNTDSLSS 252	xx
Db	219 NGTFLAYQFNQDTEVPLIEYSPYSDESLQYKPTVRYPKAGAVNPTVKKFVVNTDSLSS 278	xx
Qy	253 VTNATSIQITAPASMLGHDYLCDVTTATQRISLQWLRRTQYNSWIDICDVYDESSGRWN 312	xx
Db	279 VTNATSIQITAPASMLGHDYLCDVTTATQRISLQWLRRTQYNSWIDICDVYDESSGRWN 338	xx
Qy	313 CLVARQHTEMSITGWRFRSPPEHFTDGLNSFSYKTIISNEEYRHICYFQIDKKDCTFIT 372	xx
Db	339 CLVARQHTEMSITGWRFRSPPEHFTDGLNSFSYKTIISNEEYRHICYFQIDKKDCTFIT 398	xx
Qy	373 KGTWEVIGEALTSIDLWYISNEYKGMGGRNLWYKIQSDTYKTCUCLSELNPERCOYS 432	xx
Db	399 KGTWEVIGEALTSIDLWYISNEYKGMGGRNLWYKIQSDTYKTCUCLSELNPERCOYS 458	xx
Qy	433 VSFSKEARXYQRLRGSPGPPLTLLHSSVNDKGRLVRLDSDLKMLQNVQMPSKKLDFII 492	xx
Db	459 VSFSKEARXYQRLRGSPGPPLTLLHSSVNDKGRLVRLDSDLKMLQNVQMPSKKLDFII 518	xx
Qy	493 LNETKFWYQMLLPPHFDKSKYKPLLQDVTYAGPCSQKADTVFLNWTAYLASTENITVASF 552	xx
Db	519 LNETKFWYQMLLPPHFDKSKYKPLLQDVTYAGPCSQKADTVFLNWTAYLASTENITVASF 578	xx
Qy	553 DGRGSGYQGDKIMHAINRRLGTFEVEDQIEARQFSKGMFVDNKR1AIGNSGGYTSM 612	xx
Db	579 DGRGSGYQGDKIMHAINRRLGTFEVEDQIEARQFSKGMFVDNKR1AIGNSGGYTSM 638	xx
Qy	613 VLGSGSGYQFKCGTAVAPSRWEYDSYSTERMGLPTEPDNLDHYRNSTMSRAENFKQV 672	xx
Db	639 VLGSGSGYQFKCGTAVAPSRWEYDSYSTERMGLPTEPDNLDHYRNSTMSRAENFKQV 698	xx
Qy	673 EYLJLHGADDNTHFQQSAQISKALVGDYDDEGIGTASSTAHQHITYTMSHF 732	xx
Db	699 EYLJLHGADDNTHFQQSAQISKALVGDYDDEGIGTASSTAHQHITYTMSHF 758	xx
Qy	733 IKQCRSLP 740	xx
Db	759 IKQCRSLP 766	xx

RESULT 26

Qy	Match	Score 97.8†; Best Local Similarity 99.9†; Pred. No. 0; Matches 727; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db	13 SRKTYTITDYLKNTYRKLYSLRWISHEYLKQENNLIVVNAEYGNSSVFLNSTDEF 72	xx
Db	39 SRKTYTITDYLKNTYRKLYSLRWISHEYLKQENNLIVVNAEYGNSSVFLNSTDEF 98	xx

Db	669	YUILLINGTADDNNVHFQOSAQ1ISKALVYDGVDFQAMNYTDEDHGIASSTAHOIYTHMSHF	728	Qy	13	SRKTTTLTDYLKNTVRLKLYSLRWISDHELYKQENNLYVNAEYGNSSVPLENSTFDEF	72
Oy	73 3	IKQCFSLP	740	Db	39	SRKTTTLTDYLKNTVRLKLYSLRWISDHELYKQENNLYVNAEYGNSSVPLENSTFDEF	98
Db	729	IKQCFSLP	736	Qy	73	GHSINDYSISPDGQPTILLENYVQKMRHSTASYDIDYDLYNKRQLTTEIRIPNNTQWTS	132
RESULT 23				Db	99	GHSINDYSISPDGQFILLENYVQKMRHSTASYDIDYDLYNKRQLTTEIRIPNNTQWTS	158
ABG61910	ABG61910 standard; protein; 766 AA.			Qy	133	PVGHKLAYWNNDIVYKIEPMLPSRITWKGDEDIYNGITDWWYEEEVFAYSALWNSP	192
XX				Db	159	PVGHKLAYWNNDIVYKIEPMLPSRITWKGDEDIYNGITDWWVBBEVFAYSALWNSP	218
AC	ABG61910;			Qy	193	NGTPFLAYAQENDTEPLIEFSYSDSLOQPKTVRVPKGAVNPTVKPFVNTDSLSS	252
XX	DT 15-AUG-2002 (first entry)			Db	219	NGTPFLAYAQENDTEPLIEFSYSDSLOQPKTVRVPKGAVNPTVKPFVNTDSLSS	278
DB	Prostate cancer-associated protein #111.			Qy	253	VTNATSIQTAPASMLGDHYLCDTWATQERISLQWLRQIYNSYMDICDYDESSGRWN	312
XX	KW	Prostate cancer; prostate tumour tissue; human; mammal; cytostatic.		Db	279	VTNATSIQTAPASMLGDHYLCDTWATQERISLQWLRQIYNSYMDICDYDESSGRWN	338
OS	Mammalia.			Qy	313	CLVARORHIENSTTGWGRFRESEPFITLDGNSFYKLIISNEFGRHICYFQIDKDKCTFIT	372
XX	XX			Db	339	CLVARORHIENSTTGWGRFRESEPFITLDGNSFYKLIISNEFGRHICYFQIDKDKCTFIT	398
PD	18-APR-2002.			Qy	373	KGTWIVIGIAEATSDYLYISNEYKOMPGRNLYKIQLSDTYTKTCLSCBLNPERCQYS	432
XX	XX			Db	399	KGTWIVIGIAEATSDYLYISNEYKOMPGRNLYKIQLSDTYTKTCLSCBLNPERCQYS	458
PF	12-OCT-2001; 2001IW0-US032045.			Qy	433	VSFSEAKYVYORCSGGPGLPLYTLHSVNDKGRLRIVEDNSALDKMLQNVQMPSKRLDPFII	492
XX	PR 13-OCT-2000; 2000US-00687576.			Db	459	VSFSEAKYVYORCSGGPGLPLYTLHSVNDKGRLRIVEDNSALDKMLQNVQMPSKRLDPFII	518
PR	08-DEC-2000; 2000US-0073288.			Qy	493	LNETKTYQMLIIPPHDKSKYPLDYYAPCSCQRADTVPLNATYLASTENIIVASF	552
PR	08-DEC-2000; 2000US-0073374.			Db	519	LNETKTYQMLIIPPHDKSKYPLDYYAPCSCQRADTVPLNATYLASTENIIVASF	578
PR	24-JAN-2001; 2001US-02639577.			Qy	553	DGRGSGYQGDKIMHAIRRLGTFEVDQIEAROFSKMGFYDNKRTAIGNSYGGVYTSM	612
PR	16-MAR-2001; 2001US-0276791P.			Db	579	DGRGSGYQGDKIMHAIRRLGTFEVDQIEAROFSKMGFYDNKRTAIGNSYGGVYTSM	638
PR	16-MAR-2001; 2001US-0276888P.			Qy	613	VLGSGSEVFKGIAAPVSRMYYDSVUTERYMGLTPEDNLDHFNSTNSRAENPKQV	672
PR	06-APR-2001; 2001US-0281222P.			Db	639	VLGSGSEVFKGIAAPVSRMYYDSVUTERYMGLTPEDNLDHFNSTNSRAENPKQV	698
PR	24-APR-2001; 2001US-0286214P.			Qy	673	YUILLINGTADDNVHFOOSAQ1ISKALVYDGVDFQAMNYTDEDHGIASSTAHOIYTHM	732
PR	30-APR-2001; 2001US-028847046.			Db	699	YUILLINGTADDNVHFOOSAQ1ISKALVYDGVDFQAMNYTDEDHGIASSTAHOIYTHM	758
PR	04-MAY-2001; 2001US-0288589P.			Qy	733	IKQCFSLP	740
XX	(EOSB-) EOS BIOTECHNOLOGY INC.			Db	759	IKQCFSLP	766
PA				CC	CC	The present invention relates to methods of detecting a prostate cancer-associated transcript in a cell from a patient. The method comprises contacting a biological sample from the patient with prostate cancer-associated polynucleotides (designated PC genes) that selectively hybridise to a sequence that is at least 80% identical to them. The	RESULT 24
XX	Gish KC, Mack DH, Wilson KE, Afar D, Hevezzi P;			CC	CC	prostate cancer-associated polynucleotide sequences are differentially expressed in prostate tumour tissue or in prostate cancer and are derived from the tissues of various organisms such as humans or other mammals (e.g. mice, sheep and dogs). The methods of the invention are useful for diagnosing and treating prostate cancer in mammals. The prostate cancer-associated genes are useful for diagnosing or treating prostate cancer, as well as for identifying modulators of prostate cancer or agents that inhibit prostate cancer. The nucleic acid sequences are particularly useful in gene therapy, as a vaccine or in antisense applications.	AA015555
XX	WPI: 2002-471335/50.			CC	CC	XX	ID AA015555 standard; protein; 766 AA.
DR	DR			CC	CC	XX	AC AAO15555;
NN-PSDB; ABK22227.	NN-PSDB; ABK22227.			CC	CC	XX	XX
XX	Detecting a prostate cancer-associated transcript in a cell in a patient, useful for diagnosing prostate cancer (PC) or screening modulators of PC, by determining if prostate cancer-associated genes are expressed in a prostate tissue.			CC	CC	XX	DT 24-OCT-2002 (first entry)
PT	Claim 27; Page 393; 436pp; English.			CC	CC	XX	DB Human dipeptidyl peptidase IV (DPP IV).
PT	CC			CC	CC	XX	XX Human; angiodiemic condition; angiotensin converting enzyme; ACE; vasopeptidase inhibitor; dipeptidyl peptidase IV; aminopeptidase P; DPP IV; aminopeptidase P; APP; hypertension; diabetes; cardiac disease; renal disease; enzyme.
PT	CC			CC	CC	XX	XX Homo sapiens.
PS	Sequence 766 AA;			CC	CC	XX	OS
XX	Query Match 97.8%; Score 3933; DB 5; Length 766;			CC	CC	XX	XX
	Best Local Similarity 99.9%; Pred. No. 0;			CC	CC	XX	PN
	Matches 727; Conservative 0; Mismatches 1; Indels 0; Gaps 0;			CC	CC	XX	XX
				CC	CC	XX	WO200259343-A2.

Qy 613 VLGSGSCVPKCGIAVAVPSRMEYYDSVYTERYMGGLPTEDNLHYTRNSTMSRAENFKQV 672
 Db 639 VLGSGSCVPKCGIAVAVPSRMEYYDSVYTERYMGGLPTEDNLHYTRNSTMSRAENFKQV 698
 Qy 673 BYLLINGTADDNVRHFOOSAQIQLAKVLDGVDFQAMWYTDDEHGIASSTAHQHITYTHMSHF 732
 Db 699 BYLLINGTADDNVRHFOOSAQIQLAKVLDGVDFQAMWYTDDEHGIASSTAHQHITYTHMSHF 758
 Qy 733 IKQCFSLP 740
 Db 759 IKQCFSLP 766

RESULT 22
 ADO40240 ID ADO40240 standard; protein; 736 AA.
 AC ADO40240;
 XX DT 12-AUG-2004 (first entry)
 XX DB Human DPP-IV extracellular domain protein SEQ ID NO:2.
 XX KW crystal; mammalian dipeptidyl-peptidase IV extracellular domain;
 KW dipeptidyl-peptidase IV extracellular domain;
 KW extracellular domain; three-dimensional structure; antidiabetic;
 KW anorectic; cytostatic; type I diabetes; type II diabetes; IGT; obesity;
 KW cancer; human; DPP-IV; enzyme; protein co-ordinate data; EC 3.4.14.5.
 OS Homo sapiens.
 XX PN BP1422293-A1.
 XX PD 26-MAY-2004.
 XX PF 17-NOV-2003; 2003EP-00026169.
 XX PR 25-NOV-2002; 2002EP-00026367.
 XX PA (HOFF) HOPPMANN LA ROCHE & CO AG F.
 XX PI Hennig M, Loeffler BM, Thoma R;
 XX DR ; 2004-413363/39.
 DR N-PDB; ADO40239.
 XX PR New crystal of an extracellular domain of mammalian dipeptidyl-peptidase IV (DPP-IV) useful for identifying or designing inhibitors of DPP-IV activity.
 PR (DPP-IV) useful for identifying or designing inhibitors of DPP-IV activity.
 PS Claim 31: SEQ ID NO 2; 215pp; English.

CC identified by using (I); (10) a pharmaceutical composition (III)
 CC comprising (I) and a carrier; (11) an isolated nucleic acid sequence (IV)
 CC encoding the soluble extracellular domain of DPP-IV comprising a fully
 CC defined sequence (SEQ ID NO:1, S2) of 2211 nucleotides; (12) a nucleic
 CC acid construct (V) comprising an expression vector and (IV); (13) a host
 CC cell (VI) transformed with (V); (14) producing the soluble extracellular
 CC domain of DPP-IV, involves culturing (VI) under conditions permitting the
 CC expression of the soluble extracellular domain of DPP-IV by (VI); and
 CC (15) a polypeptide comprising the soluble extracellular domain of (S1).
 CC DPP-IV has antidiabetic, anorectic and cytostatic activities. (I) is
 CC useful for identifying a compound that interacts with DPP-IV. The
 CC compound interacts with the active site of DPP-IV. The compound interacts
 CC with an allosteric binding site of DPP-IV. The compound is an inhibitor
 CC of DPP-IV activity. (I) is useful for the identification and/or design of
 CC inhibitors of DPP-IV activity. (I) is useful as a therapeutic active
 CC substance, in particular for the treatment of diabetes type I, diabetes
 CC type II, IGT, obesity and cancer. (III) is useful for the manufacture of a
 CC medicament for the treatment of above mentioned disease. The present
 CC sequence represents the extracellular domain of human DPP-IV, which is
 CC used in the exemplification of the present invention.

Sequence 736 AA:

Query Match 97.8%; Score 3933; DB 8; Length 736;
 Best Local Similarity 99.9%; Pred. No. 0;
 Matches 727; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 13 SRKTYLTDLKNTYTRKLYSLRNISDHELYKQENNLVNAEYGNSSYFLENSTDEF 72
 Db 9 SRKTYLTDLKNTYTRKLYSLRNISDHELYKQENNLVNAEYGNSSYFLENSTDEF 68
 Qy 73 GHSINDYSISPDGGFILLEYNTYKQWRHSTASYDIDLNKRLITEERIPNNTQWVTS 132
 Db 69 GHSINDYSISPDGGFILLEYNTYKQWRHSTASYDIDLNKRLITEERIPNNTQWVTS 128
 Qy 133 PVGHKLAYTWNNDIYVKKIEPKNLPSYRITWTKBEDIYNGTIDWVYEEVPSAYSALWWSP 192
 Db 129 PVGHKLAYTWNNDIYVKKIEPKNLPSYRITWTKBEDIYNGTIDWVYEEVPSAYSALWWSP 188
 Qy 193 NGTFLAYAQFNDTEVPLIESFSYKEDSLOYPKTRVPKAGANVPTVKEFVNTDLS 252
 Db 189 NGTFLAYAQFNDTEVPLIESFSYKEDSLOYPKTRVPKAGANVPTVKEFVNTDLS 248
 Db 253 VTNATSIQITAPASMLGDRYLCPDTWATQERISLQWLRQIYNSVMDICDYSSESGRN 312
 Db 249 VTNATSIQITAPASMLGDRYLCPDTWATQERISLQWLRQIYNSVMDICDYSSESGRN 308
 Qy 313 CLVARQHITEMSTICGwgGRPSEPHFTLDGNSFVKIIISNEGGYHICYQIDKDKDCTFT 372
 Db 309 CLVARQHITEMSTICGwgGRPSEPHFTLDGNSFVKIIISNEGGYHICYQIDKDKDCTFT 368
 Qy 373 KGTREVGIGBALSDYLLTISNEVKGMPGRNLVYKIQSLSDYTKTCLSCBLNPRCQYYS 432
 Db 369 KGTREVGIGBALSDYLLTISNEVKGMPGRNLVYKIQSLSDYTKTCLSCBLNPRCQYYS 428
 Qy 433 VSPFKEAKYQLRCSGPGLPLYTHSSYNDKGILRVLDENSALDQNLQVYQMPSKRLDFII 492
 Db 429 VSPFKEAKYQLRCSGPGLPLYTHSSYNDKGILRVLDENSALDQNLQVYQMPSKRLDFII 488
 Qy 493 LNETKFWYOMILPHEFDKSKKYPPLDYYAGPCSKQADTVLNRWATYLASTENIVAVSP 552
 Db 489 LNETKFWYOMILPHEFDKSKKYPPLDYYAGPCSKQADTVLNRWATYLASTENIVAVSP 548
 Qy 553 DGRSSGYQDDKIMHAINRRLGTPEVEDQIBEARQFSKQGFDVNRKRIATMGWSYCYVTSM 612
 Db 549 DGRSSGYQDDKIMHAINRRLGTPEVEDQIBEARQFSKQGFDVNRKRIATMGWSYCYVTSM 608
 Qy 613 VLGSSGSGYVKFCGIAVAPSRWEYDSVTERYMLPTPENLDTYRNSTMSRAENFKQV 672
 Db 609 VLGSSGSGYVKFCGIAVAPSRWEYDSVTERYMLPTPENLDTYRNSTMSRAENFKQV 668
 Qy 673 EYLJHGADDNTHFQOQSAQISKALVYDGVDFOMWYTFEDHGJASSTAHQHITYTHMSHF 732

Qy 613 VLGSGSGVFKCGIAYAPVSRWBYDSVTTBRMGLPTPEIDNLDHYRNSTVMSRAENFKVY 672
 Db 639 VLGSGSGVFKCGIAYAPVSRWBYDSVTTBRMGLPTPEIDNLDHYRNSTVMSRAENFKVY 698

Qy 673 BYLLIQTADDNVHFOQSAQISKALVYDGVDFQAMWYTDDEHGIASSTAHQHITYTHMSHF 732
 Db 699 BYLLIQTADDNVHFOQSAQISKALVYDGVDFQAMWYTDDEHGIASSTAHQHITYTHMSHF 758

Qy 733 IKQCFSLP 740
 Db 759 IKQCFSLP 766

RESULT 21
 AEB94223 standard; protein; 766 AA.
 XX
 AEB94223;
 XX
 DT 06-OCT-2005 (first entry)

DE CD26/dipeptidyl peptidase IV (DPPIV) SEQ ID NO:66.

XX immune inhibition; fibroblast activation protein alpha dimer; ;
 KW PAP alpha dimer; guillain-barre syndrome; antiinflammatory; cns-gen.; ;
 KW immune disorder; neurological disease; autoimmune disease; ;
 KW immunosuppressive; graft versus host disease; transplant rejection; ;
 KW endotoxic shock; osteoarthritis; antiarthritic; osteopathic; ;
 KW musculoskeletal disease; allergy; antiallergic; asthma; antiasthmatic; ;
 KW inflammation; respiratory disease; atherosclerosis; antiarteriosclerotic; ;
 KW cardiovascular disease; metabolic disorder; hashimoto disease; ;
 KW antithyroid; endocrine disease; inflammatory bowel disease; ;
 KW antiinflammatory; gastrointestinal-gen.; Gastrointestinal disease; ;
 KW rheumatoid arthritis; anti rheumatic; multiple sclerosis; neuroprotective; ;
 KW autoimmune hepatitis; antiinflammatory; hepatotropic; ;
 KW systemic lupus erythematosus; dermatological; dermatological disease; ;
 KW uveitis; ophthalmological; autoimmune hemolytic anemia; anti anemic; ;
 KW hematological disease; rheumatic fever; antipyretic; Crohns disease; ;
 KW psoriasis; antipsoriatic; graves disease; antithyroid; ;
 KW respiratory syncytial virus infection; respiratory-gen.; virucide; ;
 KW CD26 dipeptidyl peptidase IV; DPPIV.

XX Homo sapiens.
 PN WO2005071073-A1.
 XX 04-AUG-2005.
 PD 10-JAN-2005; 2005WO-US000709.
 PR 09-JAN-2004; 2004US-0535577P.
 PA (POIN-) POINT THERAPEUTICS INC.
 XX McLean PA, Jones B, Miller GT, Jason MI;
 XX WPI; 2005-564220/57.
 XX Down-regulating an immune response comprises administering to a subject
 PT in need a fibroblast activation protein (PAP) alpha dimer enzyme in an
 PT amount effective to down-regulate an immune response.
 XX Disclosure; SEQ ID NO 66; 17pp; English.
 PS

XX The invention relates to a method of down regulating an immune response,
 CC which comprises administering to a subject a fibroblast activation
 protein (PAP) alpha dimer enzyme in an amount effective to down-regulate
 an immune response. Also included are the following: a composition
 comprising a PAP alpha dimer enzyme in a pharmaceutically acceptable
 carrier, where the composition is sterile and lacks an adjuvant; a
 composition comprising PAP alpha dimer enzyme in a pharmaceutical
 acceptable carrier, and a non-adjuvant second agent; a composition
 comprising a PAP alpha dimer enzyme comprising an amino acid substitution

CC of A657D; and a composition comprising a PAP alpha dimer enzyme lacking
 CC amino acids 269-448 and comprising amino acids 269-448 from mouse PAP.
 CC The method further comprises administering to the subject a second agent.
 CC The second agent is an anti-inflammatory agent, immunosuppressant, or
 CC anti-infective agent such as antibacterial, antiviral, antifungal, anti-
 CC parasitic or anti-mycobacterial agent. The PAP alpha dimer enzyme is wild
 CC type PAP alpha dimer enzyme. The PAP alpha dimer enzyme is a truncation
 CC mutant. The PAP alpha dimer enzyme is a fusion or chimeric protein. The
 CC PAP alpha dimer enzyme is a heterodimer of a PAP alpha monomer and a
 CC DPPIV/CD26 monomer. The PAP alpha dimer enzyme comprises an amino acid
 CC substitution relative to wild type PAP alpha dimer. The amino acid
 CC substitution is present in the beta-propeller domain, the catalytic
 CC domain, or an N-linked glycosylation site and alters disulfide bond
 CC formation. The immune response is an especially an IL-1 mediated
 CC condition, abnormal immune response selected from inflammation,
 CC autoimmune disease, sepsis, graft versus host disease, transplant
 CC rejection, toxic shock syndrome, allergy, asthma, atherosclerosis,
 CC osteoarthritis, and Guillain-Barre's syndrome. The abnormal immune
 CC response is subsequent to an infection, such as an RSV infection. The
 CC autoimmune disease is selected from c, autoimmune thyroiditis, systemic
 CC lupus erythematosus (SLE), uveitis, hemolytic anemias, rheumatic fever,
 CC Crohn's disease, Guillain-Barre's syndrome, psoriasis, Graves' disease,
 CC myasthenia gravis, glomerulonephritis, autoimmune hepatitis and multiple
 CC sclerosis. The subject does not have cancer or a predisposition to
 CC cancer. The present sequence represents the amino acid sequence of human
 CC CD26/dipeptidyl peptidase IV (DPPIV).
 XX
 SQ Sequence 766 AA:

Query Match	98.0%	Score 3939;	DB 9;	Length 766;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches	728;	Conservative 0;	Mismatches 0;	Indels 0;
				Gaps 0;

Qy 13 SRKTYLTIDYKNTNTRKLKYSLRWSDHEVLYKQENNLVFNAYEKGNSVYLENSFDFP 72
 Db 39 SRKTYLTIDYKNTNTRKLKYSLRWSDHEVLYKQENNLVFNAYEKGNSVYLENSFDFP 98
 Qy 73 GHSINDYSSPDQGFLLENYVKQWRSHTASYDIDLNKRQLTEERIPNTNTQWTS 132
 Db 99 GHSINDYSSPDQGFLLENYVKQWRSHTASYDIDLNKRQLTEERIPNTNTQWTS 158
 Qy 133 PVGHKLAYWNNDIYTKIEPNLPSRITWTGKEDDIYNGTIDWVYEEVEEVSAYSLWNSP 192
 Db 159 PVGHKLAYWNNDIYTKIEPNLPSRITWTGKEDDIYNGTIDWVYEEVEEVSAYSLWNSP
 Qy 193 NGTFLAYAQFDNTVPEPIEYSPYSDLSQYPTKVRPYPKAGAVNPVKFFVNNTDLS 252
 Db 219 NGTFLAYAQFDNTVPEPIEYSPYSDLSQYPTKVRPYPKAGAVNPVKFFVNNTDLS 278
 Qy 253 VTNATSTQITAPASMLGJDHYLCDYTWATQRISLWLRRIQNSYMDICDDESSGRWN 312
 Db 279 VTNATSTQITAPASMLGJDHYLCDYTWATQRISLWLRRIQNSYMDICDDESSGRWN 338
 Qy 313 CLVARQHIELMSTGHWGTRISLWLRRIQNSYMDICDDESSGRWN 372
 Db 339 CLVARQHIELMSTGHWGTRISLWLRRIQNSYMDICDDESSGRWN 398
 Qy 373 KGTWEVIGIAUTSDYIYISNEYKMPGGNLYKQLSDTPTKVTCLSCINPERCQYS 432
 Db 399 KGTWEVIGIAUTSDYIYISNEYKMPGGNLYKQLSDTPTKVTCLSCINPERCQYS 458
 Qy 433 VSFSKBEAKYQYURCSGPGLPLYTHSSYNDKGRLVIEDNSALDKMQLQVNPMSKCLDFI 492
 Db 459 VSFSKBEAKYQYURCSGPGLPLYTHSSYNDKGRLVIEDNSALDKMQLQVNPMSKCLDFI 518
 Qy 493 LNETKFWYQMLPPDKPSKCKYPLLDVYAGPSCSKQADTVPLRNWATYLASTENIIVASF 552
 Db 519 LNETKFWYQMLPPDKPSKCKYPLLDVYAGPSCSKQADTVPLRNWATYLASTENIIVASF 578
 Qy 553 DERRSGYQGDKIMHAINRRLGTFEVQIAROFSONGVDNKRIAWGAGYGNFTSM 612
 Db 579 DERRSGYQGDKIMHAINRRLGTFEVQIAROFSONGVDNKRIAWGWSYGYVFTSM 638

Db	39	SRKTYLTIDYKNTYTRKLKYSLRWSIDHEVYKQENNLIVNAYCQNSSYPLENSSTDEF	98	PR 03-OCT-2003; 2003US-0508699P.
Qy	73	GHSINDYSISPDGQFILETINYKQWHRSTASYDIDLNRQLTERIPLNNTQWTWS	132	XX PA (HOFF) HOFFMANN LA ROCHE INC.
Db	99	GHSINDYSISPDGQFILETINYKQWHRSTASYDIDLNRQLTERIPLNNTQWTWS	158	XX PI Kochan JP, Martin ML, Rosinski JA;
Db	133	PVGHKLAVYWNNDIYKIEPULPSRTIWTGKEDITYNGITDWWYEEBEVSAYSAIWWS	192	XX DR WPI: 2005-283780/29.
Qy	159	PVGHKLAVYWNNDIYKIEPULPSRTIWTGKEDITYNGITDWWYEEBEVSAYSAIWWS	218	XX DR N-PSDB; ADZ14037.
Db	193	NGTFLAYAQENDTEVPLIEFSYFSDESQYPKTRVVPYKAGAVNPTVKFVNTDS	252	XX DR REFSEQ; NP_001926.
Qy	219	NGTFLAYAQENDTEVPLIEFSYFSDESQYPKTRVVPYKAGAVNPTVKFVNTDS	278	XX PT Diagnosing pre-diabetes, diabetes or susceptibility to diabetes, by obtaining biological sample, and detecting or measuring level of polypeptide marker comprising polypeptide e.g. vascular endothelial growth factor B, apolipoprotein D.
Qy	253	VTNATSIQITAPASMLIGDHYLDCVWATERISLQWLR1QNYSMIDCYDESSGRWN	312	XX PS Claim 1: SEQ ID NO 18; 66pp; English.
Db	279	VTNATSIQITAPASMLIGDHYLDCDWTWATERISLQWLR1QNYSMIDCYDESSGRWN	338	XX The present invention relates to a method for diagnosing of pre-diabetes diabetes or susceptibility to diabetes. The method involves obtaining a biological sample and detecting or measuring the level of a polypeptide marker, such as vascular endothelial growth factor B or apolipoprotein D. The invention is useful for treating diabetes and pre-diabetes. The present sequence is the human dipeptidyl peptidase IV (DPPIV, ADAPB). Dipeptidyl Peptidase IV is also known as CD26, ADCP2, TP103, ADABP; adenosine deaminase complexing protein 2 and Tcell activation antigen CD26.
Qy	313	CLVAROHIEMSTTGWYGRFRESEPHFTLDGNSFYKIIISNEEGYRHYCQIDKEDCTFT	372	XX Sequence 766 AA;
Db	339	CLVAROHIEMSTTGWYGRFRESEPHFTLDGNSFYKIIISNEEGYRHYCQIDKEDCTFT	398	CC Query Match 98.0%; Score 3939; DB 9; Length 766;
Qy	373	KGTWEVIGIERTLSDYK11YSNEYGKMPGMRNLKIQSLTYTCKLSCELNPERCQYTS	432	CC Best Local Similarity 100.0%; Pred. No 0;
Db	399	KGTWEVIGIERTLSDYK11YSNEYGKMPGSRNLKIQSLTYTCKLSCELNPERCQYTS	458	CC Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	433	VFSFKEAKYQLRCSGPGPLAYLHSSVNDKGLRVLDELDNSALDKMLQNYQMPSKKLDFTI	492	CC Query 13 SRKTYLTIDYKNTYTRKLKYSLRWSIDHEVYKQENNLIVNAYCQNSSYPLENSSTDEF 72
Db	459	VFSFKEAKYQLRCSGPGPLAYLHSSVNDKGLRVLDELDNSALDKMLQNYQMPSKKLDFTI	518	CC Db 39 SRKTYLTIDYKNTYTRKLYSRNTISDHEVYKQENNLIVNAYCQNSSYPLENSSTDEF 98
Qy	493	LNETKFWYQMLLPPFDKSCKYPLIDYYAGPCSKQADTVFRLWATYLASTENIVASF	552	CC Qy 73 GHSINDYSISPDGGQFILLEYNNVQWHRSYTASTDIYDINKRQLTTEIRIPLNNTQWTWS 13
Db	519	LNETKFWYQMLLPPFDKSCKYPLIDYYAGPCSKQADTVFRLWATYLASTENIVASF	578	CC Db 99 GHSINDYSISPDGQFILLEYNNVQWHRSYTASDIYDINKRQLTTEIRIPLNNTQWTWS 15
Qy	553	DGRSGGGYQGKIMHAINRRLGTFVYDQTEAARQFSKMGFVDNKR1ATIGWSYGGYVTSM	612	CC Db 133 PVGHKLAYWNNDIYK11NPYKTYTGFEDITYNGITDWWYEEEVSYASALWWSP 19
Db	579	DGRSGGGYQGKIMHAINRRLGTFVYDQTEAARQFSKMGFVDNKR1ATIGWSYGGYVTSM	638	CC Db 159 PVGHKLAYWNNDIYK11NPYKTYTGFEDITYNGITDWWYEEEVSYASALWWSP 21
Qy	613	VLGSGSGVFKCGIAVAPYPSRWEYDSSVYTERYMGGLPTEDNLHYRNTSTMRAENFKQY	672	CC Db 193 NGTFLAYAQENDTEVPLIEFSYFSDESQYPKTRVVPYKAGAVNPTVKFVNTDS
Db	639	VLGSGSGVFKCGIAVAPYPSRWEYDSSVYTERYMGGLPTEDNLHYRNTSTMRAENFKQY	698	CC Db 219 NGTFLAYAQENDTEVPLIBSYFSYDESQYPKTRVVPYKAGAVNPTVKFVNTDS
Qy	673	EYLIJHGTTADDNHFQOQAQSKALVDVGDFQAMWYTDGDHGIASTAHQH1YTHMSHF	732	CC Db 253 VTNATSIQITAPASMLGDHYLDCVWATERISLQWLR1QNYSMIDCYDESSGRWN 31
Db	699	EYLIJHGTTADDNHFQOQAQSKALVDVGDFQAMWYTDGDHGIASTAHQH1YTHMSHF	758	CC Db 279 VTNATSIQITAPASMLGDHYLDCVWATERISLQWLR1QNYSMIDCYDESSGRWN 33
Qy	733	IKQCFSLP 740		CC Qy 313 CLVARQHIMSTTGWGRPRPSEPHFTLDGNSFYKPLDYYAGPCSKQADTVFRLWATYLASTENIVASP 55
Db	759	IKQCFSLP 766		CC Db 339 CLVARQHIMSTTGWGRPRPSEPHFTLDGNSFYKPLDYYAGPCSKQADTVFRLWATYLASTENIVASP 57
Qy	800	RESULT 20		CC Qy 373 KGTWEVIGIERTLSDYK11YSNEYGKMPGMRNLKIQSLTYTCKLSCELNPERCQYTS 43
Id	AD214038	AD214038 standard; protein; 766 AA.		CC Db 399 KGTWEVIGIERTLSDYK11YSNEYGKMPGMRNLKIQSLTYTCKLSCELNPERCQYTS 45
Qy	801	AD214038;		CC Qy 433 VSFKEAKYQLRCSGPGPLYTHSSYNDKGFLRVSYDQKADTVFRLWATYLASTENIVASP 55
Db	802	16-JUN-2005 (first entry)		CC Db 459 VSFKEAKYQLRCSGPGPLYTHSSYNDKGFLRVSYDQKADTVFRLWATYLASTENIVASP 57
Qy	803	Human dipeptidyl peptidase IV protein.		CC Qy 493 LNETKFWYQMLLPPFDKSCKYPLIDYYAGPCSKQADTVFRLWATYLASTENIVASP 55
Db	804	diabetes; anti-diabetic; endocrine disease; gastrointestinal disease;		CC Db 519 LNETKFWYQMLLPPFDKSCKYPLIDYYAGPCSKQADTVFRLWATYLASTENIVASP 57
Qy	805	metabolic disorder; dipeptidyl peptidase IV; CD26; enzyme.		CC Qy 553 DGRSGGYQGDKIMHAINRRLGTFVYDQTEAARQFSKMGFVDNKR1ATIGWSYGGYVTSM 61
Os	806	Homo sapiens.		CC Qy 579 DGRSGGYQGDKIMHAINRRLGTFVYDQTEAARQFSKMGFVDNKR1ATIGWSYGGYVTSM 63
Xx	807	US2005074805-A1.		
Xx	808	07-APR-2005.		
Db	809	28-SEP-2004; 2004US-00952459.		

KW	Antiinflammatory; Immune disorder; Dermatological; Immunosuppressive;	Qy	493 LNETKEWYQMLPPFDKSKYPLLLDYYAGPCSCQKADTVRLNQVATYLASTENIVASP 552
KW	Antichrionic; Antiarthritic; Osteoarthritis; Hemostatic; Antianemic;	Db	519 LNETKEWYQMLPPFDKSKYPLLLDYYAGPCSCQKADTVRLNQVATYLASTENIVASP 578
KW	Antidiabetic; Nephrotoxic; CNS-Gen.; Hepatotoxic; Antiarachmatic;	Qy	553 DGRGSGYQGDKIMHAINRRLGTPEYDQEAAQFQKMGFDNKRKIAIWGMSYGGYTM 612
KW	Antiallergic; ds; gene; diagnosis.	Db	579 DGRGSGYQGDKIMHAINRRLGTPEYDQEAAQFQKMGFDNKRKIAIWGMSYGGYTM 638
XX		Qy	613 VLGSQSGVFKCGIAAPVSRVBYYDSEVTYRGMGLPTPEDNLHDYRNSTNSRAENFKQV 672
OS	Homo sapiens.	Db	639 VLGSQSGVFKCGIAAPVSRVBYYDSEVTYRGMGLPTPEDNLHDYRNSTNSRAENFKQV 698
PN	WO2005016962-A2.	Qy	673 EYLHGTADNVHFOQSAQISKALVQGVDFQAMWYTDDEHGIASSTAHOHYTMSHF 732
XX	PD 24-FEB-2005.	Db	699 EYLHGTADNVHFOQSAQISKALVQGVDFQAMWYTDDEHGIASSTAHOHYTMSHF 758
XX	PP 11-AUG-2004; 2004WO-US026249.	Qy	733 IKQCPFLP 740
XX	PR 11-AUG-2003; 2003US-0493546P.	Db	759 IKQCPFLP 766
XX	PA (GETH) GENENTECH INC.	RESULT 19	
XX	Abbas A, Clark H, Ouyang W, Williams MP, Wood WI, Wu TD;	ADY16580	ADY16580 standard; protein; 766 AA.
PI	WPI; 2005-182330/19.	XX	XX PRO polypeptide SEQ ID NO 2386.
XX	PT New nucleic acid encoding PRO polypeptide, useful for diagnosing and	XX	XX Antiinflammatory; Immune disorder; Dermatological; Immunosuppressive;
PT	treating an immune related disorder, e.g. systemic lupus erythematosus,	XX	XX Antirheumatic; Antiarthritic; Osteoarthritis; Hemostatic; Antianemic;
PT	rheumatoid arthritis, osteoarthritis, thyroiditis, or diabetes mellitus.	XX	XX Antithyroid; Antidiabetic; Nephrotoxic; CNS-Gen.; Hepatotoxic;
PS	PS; SEQ ID NO 967; 158pp; English.	XX	XX Virucide; Gastrointestinal-Gen.; Antipsoriatic; Antiarachmatic;
XX	The invention relates to an isolated nucleic acid encoding a PRO	XX	XX Antiallergic; ds; gene; diagnosis.
CC	polypeptide. The polypeptide, agonist or an antagonist, antibody,	XX	XX Homo sapiens.
CC	composition, and method are useful for diagnosing and treating an immune	XX	XX WO2005016962-A2.
CC	related disorder, e.g. systemic lupus erythematosus, rheumatoid	XX	XX PRO polypeptide SEQ ID NO 2386.
CC	arthritis. The present sequence represents a DNA encoding a PRO	XX	XX DT 05-MAY-2005 (first entry)
CC	polypeptide.	XX	XX DB 24-FEB-2005.
XX	Sequence 766 AA;	XX	XX AC ADY16580;
XX	Query Match 98.0%; Score 3939; DB 9; Length 766;	XX	XX AC ADY16580;
Best Local Similarity 100.0%; Pred. No. 0;	Matches 728; Conservative 0; Mismatches 0; Gaps 0;	XX	XX PR 11-AUG-2003; 2003US-0493546P.
Db	99 GHSINDYTSISPGQFILYKLVKLYSLRWSIDHELYKQKENNIVLVAEYGNSSVPLENSIDDEF 72	XX	XX XX (GETH) GENENTECH INC.
Db	39 SRKTYTLDYLTDLKNTYRKLKLYSLRWSIDHELYKQKENNIVLVAEYGNSSVPLENSIDDEF 98	XX	XX PD 11-AUG-2004; 2004WO-US026249.
Qy	73 GHSINDYTSISPGQFILYKLVKLYSLRWSIDHELYKQKENNIVLVAEYGNSSVPLENSIDDEF 132	XX	XX XX WPI; 2005-182330/19.
Db	99 GHSINDYTSISPGQFILYKLVKLYSLRWSIDHELYKQKENNIVLVAEYGNSSVPLENSIDDEF 158	XX	XX PT New nucleic acid encoding PRO polypeptide, useful for diagnosing and
Qy	133 PVGHKLAYVWNNDIYVKEIPNLPSYRITWKGKEDILYNGITDWWYBEEVSAYSALWWSP 192	XX	XX PT treating an immune related disorder, e.g. systemic lupus erythematosus,
Db	159 PVGHKLAYVWNNDIYVKEIPNLPSYRITWKGKEDILYNGITDWWYBEEVSAYSALWWSP 218	XX	XX PT rheumatoid arthritis, osteoarthritis, thyroiditis, or diabetes mellitus.
Qy	193 NGTFLAYAQNDTEVPLIEYSPYSDS1LQYKPTVRYPKAGAVNPPTVKFFVNTDSLSS 252	XX	XX DR WPI; 2005-182330/19.
Db	219 NGTFLAYAQNDTEVPLIEYSPYSDS1LQYKPTVRYPKAGAVNPPTVKFFVNTDSLSS 278	XX	XX PS Claim 8; SEQ ID NO 2386; 158pp; English.
Qy	253 VTNATSIQITAPASMLQDGHYLCDVTTQATQBSLQWLRRTQNSYMDICDYDESSGRN 312	XX	XX CC The invention relates to an isolated nucleic acid encoding a PRO
Db	279 VTNATSIQITAPASMLQDGHYLCDVTTQATQBSLQWLRRTQNSYMDICDYDESSGRN 338	CC	CC polypeptide. The polypeptide, agonist or an antagonist, antibody,
Qy	313 CLVARQHLEMSTIGWGRFRPSEPHFTLDGNSFYKTLISNEGYRHICYFQIDKKDCTFIT 372	CC	CC composition, and method are useful for diagnosing and treating an immune
Db	339 CLVARQHLEMSTIGWGRFRPSEPHFTLDGNSFYKTLISNEGYRHICYFQIDKKDCTFIT 398	CC	CC related disorder, e.g. systemic lupus erythematosus, rheumatoid
Qy	373 KGTWEVIGEALTSIDLVYISBYKGMPGGRNLKYQSLDVTKTCISCELNPEROYCS 432	CC	CC arthritis. The present sequence represents a DNA encoding a PRO
Db	399 KGTWEVIGEALTSIDLVYISBYKGMPGGRNLKYQSLDVTKTCISCELNPEROYCS 458	CC	CC polypeptide.
Qy	433 VSFSKEAKXYQRLCSGPPLTLHSSVNDKGRLVLEDNSALDKMLQNVQMPSKCLDFII 492	XX	XX SQ Sequence 766 AA;
Db	459 VSFSKEAKXYQRLCSGPPLTLHSSVNDKGRLVLEDNSALDKMLQNVQMPSKCLDFII 518	XX	XX Query Match 98.0%; Score 3939; DB 9; Length 766;
Qy	13 SRKTYTLDYLTDLKNTYRKLKLYSLRWSIDHELYKQENNIVFNAEYGNSSVFLENSTDEF 72	XX	XX Best Local Similarity 100.0%; Pred. No. 0;
Db		XX	XX Matches 728; Conservative 0; Mismatches 0; Gaps 0;

Db 639 VLGSGSGVPKCGTAVAVPVSREYYDSUTTERYMGGLPPEDNLHDYRNTMSRAENFKQV 698
 Qy 673 EYLLIHGSTDADDNYHFOOSAISKALVQVGDFOAMMVTDEDHGIASTAHQHITYTMSHF 732
 Db 699 EYLLIHGSTDADDNYHFOOSAISKALVQVGDFOAMMVTDEDHGIASTAHQHITYTMSHF 758
 Qy 733 IKQCPSLP 740
 Db 759 IKQCPSLP 766

RESULT 17
 ADV25525
 ID ADV25525 standard; protein; 766 AA.
 XX
 DT 24-FEB-2005 (first entry)
 XX
 DE Human dipeptidyl-peptidase IV.
 XX
 Dipeptidyl-peptidase IV; DPP4; cardiovascular disease;
 KW respiratory disease; cancer; neoplasm; hematological disease;
 KW metabolic disorder; Gastrointestinal disease; liver disease;
 KW Endocrine-Gen.; Cardiovascular Gen.; Antinflammatory;
 KW Gastrointestinal-Gen.; Gynecological; Hepatotropic;
 KW Neuroprotective; Cystostatic; Antiparkinsonian; Notropic; Cardiotropic;
 KW Antiarrhythmic; Antiarteriosclerotic; Antianemic; Antidiabetic;
 KW Dermatological; Immunosuppressive; Muscular-Gen.; Antirheumatic;
 KW Antiarthritic; Antipsoriatic; Antifertility; Gene Therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO2004104216-A2.
 XX
 PD 02-DEC-2004.
 XX
 PP 12-MAY-2004; 2004WO-EP005071.
 XX
 PR 21-MAY-2003; 2003EP-00011481.
 XX
 PA (PARB) BAYER HEALTHCARE AG.
 XX
 PI Golz S, Brueggemeier U, Summer H;
 XX
 DR WPI: 2004-834301/82.
 XX
 DR N-PSDB; ADV25524.

Use of dipeptidylpeptidase IV (DPP4) polypeptides or polynucleotides for screening therapeutic agents or for diagnosing or treating diseases associated with DPP4, e.g. cardiovascular, metabolic, inflammatory, or neurological disorders.

Disclosure: SEQ ID NO 2; 128pp; English.

The present sequence is the protein sequence of human dipeptidyl-peptidase IV (DPP4). The invention relates to novel disease associations of DPP4 polypeptides and polynucleotides and to novel methods of screening for therapeutic agents for the treatment of cardiovascular disorders, dermatological disorders, cancer, hematological disorders, respiratory diseases, gastrointestinal and liver diseases, urological disorders and metabolic diseases. Pharmaceutical compositions are provided for treatment of these diseases and disorders and comprise a DPP4 polypeptide, a DPP4 polynucleotide, or regulators of DPP4 or modulators of DPP4 activity. The therapeutic agent is preferably a small molecule, an RNA molecule, an antisense oligonucleotide, a polypeptide, an antibody or a ribozyme. The invention also provides methods of diagnosing diseases and disorders associated with DPP4, by measuring the amount of a DPP4 polynucleotide in a sample and comparing it with the amount in a sample from a healthy and/or diseased mammal. The diseases and disorders include Parkinson's disease, dementia, Alzheimer's disease, myocardial infarction, arrhythmias, atherosclerosis, anemia, eosinophilic disorders, leukemia, pancreatitis, Crohn's disease, inflammatory bowel

CC disease, diabetes, Cushing's syndrome, systemic lupus erythematosus, CC myasthenia gravis, rheumatoid arthritis, psoriasis, scleroderma, or CC infertility.
 XX
 SQ Sequence 766 AA;

Query Match 98.0%; Score 3939; DB 8; Length 766;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 SRKTYLTDYLNTRKLYSLRWISDHETLYKQENNLVYNAEYGNNSVYLENSTFDEF 72
 Db 39 SRKTYLTDYLNTRKLYSLRWISDHETLYKQENNLVYNAEYGNNSVYLENSTFDEF 98

Qy 73 GHSHNDYISSPDGFILLENYVQWRHSYTASDYLINKQLITERIPNTTQWTS 132
 Db 99 GHSHNDYISSPDGFQFILLENYVQWRHSYTASDYLINKQLITERIPNTTQWTS 158

Qy 133 PVGHLAYWNNNDTVKIEBNPLSPRTWNGKEDITYNGTIDWYEEBEVSAYSAWMWSP 192
 Db 159 PVGHKLLAYWNNNDTVKIEBNPLSPRTWNGKEDITYNGTIDWYEEVSAYSAWMWSP 218

Qy 193 NGTFLAYAQFNDTVEPLIETFSYSDLSQPKTVRVPYKAGAVNPTVKFVVNTDLS 252
 Db 219 NGTFLAYAQFNDTVEPLIETFSYSDLSQPKTVRVPYKAGAVNPTVKFVVNTDLS 278

Qy 253 VTNATSIQITAPASMLIGHYLCUTWQERISLWRIQNSYMDICDYEDESGRWN 312
 Db 279 VTNATSIQITAPASMLIGHYLCUTWQERISLWRIQNSYMDICDYEDESGRWN 338

Qy 313 CLVAQHIENSTGIVGNGRPPSEPHFTLDNSPFIKLIISNEGGHRYCIPQDQDCTFIT 372
 Db 339 CLVAQHIENSTGIVGNGRPPSEPHFTLDNSPFIKLIISNEGGHRYCIPQDQDCTFIT 398

Qy 373 KGTWVGIEBALTDYLYTISNEYKGMPCGRNLTKIQLSDYTKYTCLSCELNPERCQYYS 432
 Db 399 KGTWVGIEALTDYLYTISNEYKGMPCGRNLTKIQLSDYTKYTCLSCELNPERCQYYS 458

Qy 433 VSPSKBACYQOLRCSGPGLPLYTHSSNDKGFLWEDNSALDKMQLQYQMPSKLQDFII 492
 Db 459 VSPSKBACYQOLRCSGPGLPLYTHSSNDKGFLWEDNSALDKMQLQYQMPSKLQDFII 518

Qy 493 LNEFKWYQMLPQHFDKSKKYPILLDLYAGPCQKADTYFRWQWATYLASTNTIVASP 552
 Db 519 LNEFKWYQMLPQHFDKSKKYPILLDLYAGPCQKADTYFRWQWATYLASTNTIVASP 578

Qy 553 DGRGSGYQGDPKIMHAINRRLGTFEVEDQI BAARDFSKMGMFDNRKIAITGWSYGGYVTSM 612
 Db 579 DGRGSGYQGDPKIMHAINRRLGTFEVEDQI BAARDFSKMGMFDNRKIAITGWSYGGYVTSM 638

Qy 613 VLGSSGIVPKCGIAAVAPVSRWEYDSVTERYMLGPTPDDNLDTYRNSTMSRAENFKQV 672
 Db 639 VLGSSGIVPKCGIAAVAPVSRWEYDSVTERYMLGPTPDDNLDTYRNSTMSRAENFKQV 698

Qy 673 EYLILHGSTDADDNYHFOQSQISKALVQGDYDFQAMWYTDBDHGASSTAHQHITHMSHF 732
 Db 699 EYLILHGSTDADDNYHFOQSQISKALVQGDYDFQAMWYTDBDHGASSTAHQHITHMSHF 758

RESULT 18
 ADV15161
 ID ADV15161 standard; protein; 766 AA.
 XX
 AC ADV15161;
 DT 05-MAY-2005 (first entry)
 DE PRO polypeptide SEQ ID NO 967.

Db 159 PVGHIKLLAYWNNDIYVYKIEPNLPSYRITWKGKEDIYNGITDWWVYEEBVEFSAWSLWSP 218
 Qy 193 NGTFLAYAQFDNTEVPLIEYSFSYDSLSQYKTRVPPYKAGAVNPTVKEFVNTDSLSS 252
 Db 219 NGTFLAYAQFDNTEVPLIEYSFSYDSLSQYKTRVPPYKAGAVNPTVKEFVNTDSLSS 278
 Db 253 VTNATSIQITAPASMLIGDHYLCDVTAQTRISLWLRRIQYNSMDICDYDESSGRNN 312
 Qy 279 VTNATSIQITAPASMLIGDHYLCDVTAQTRISLWLRRIQYNSMDICDYDESSGRNN 338
 Db 313 CLVARQHIEMSTGTYWGRFRSEPHFTLDGNSFYKTIISNEGYRATICYQFDKDKDTFT 372
 Qy 339 CLVARQHIEMSTGTYWGRFRSEPHFTLDGNSFYKTIISNEGYRATICYQFDKDKDTFT 398
 Qy 373 KTWETVIGIEALTSIDLVYISNEYKGMGPGRNLYKIQLSDTYTCKVTCISCLNPERQYYS 432
 Db 399 KGTWTETVIGIEALTSIDLVYISNEYKGMGPGRNLYKIQLSDTYTCKVTCISCLNPERQYYS 458
 Qy 433 VSFSKERAKYYQQLRCSGFPGLPLTYLHSVNDKGRLVEEDNSALDKMQLQVNPMSKQLDFII 492
 Db 459 VSFSKERAKYYQQLRCSGFPGLPLTYLHSVNDKGRLVEEDNSALDKMQLQVNPMSKQLDFII 518
 Qy 493 LNETKFWYQMLPPHDKSKYKPLLLDVYAGPCSQADTVFRLNATYLASTENIVASF 552
 Db 519 LNETKFWYQMLPPHDKSKYKPLLLDVYAGPCSQADTVFRLNATYLASTENIVASF 578
 Qy 553 DGRGSGYQGDKIMHAIRNRLGTFEVEDQIEARQFSRMGFVDNKR1AWGNSGGYVTSM 612
 Db 579 DGRGSGYQGDKIMHAIRNRLGTFEVEDQIEARQFSRMGFVDNKR1AWGNSGGYVTSM 638
 Qy 613 VLGSGSCEVKCGIAVAPVSRWEYDSVTEYMGPLPTEDNLDHYTNSTMSRAENFKQV 672
 Db 639 VLGSGSCEVKCGIAVAPVSRWEYDSVTEYMGPLPTEDNLDHYTNSTMSRAENFKQV 698
 Qy 673 BYLLINGTADDNHFQQAQTSKALYDVGDFQAMPTTDEDHGIASSTAQHIIYTMSHF 732
 Db 699 BYLLINGTADDNHFQQAQTSKALYDVGDFQAMPTTDEDHGIASSTAQHIIYTMSHF 758
 Qy 733 IKQCFSLP 740
 Db 759 IKQCFSLP 766

RESULT 16
 ID ADU06688 standard: protein; 766 AA.
 AC ADU06688;
 DT 27-JAN-2005 (first entry)
 XX Novel bronchial cancer-associated human protein SegID914.
 KW bronchial cancer; cytostatic; tumour-associated protein;
 KW cancer detection; metastasis; tumour; human.
 Homo sapiens.
 XX DE10316701-A1.
 PN 09-APR-2003; 2003DE-01016701.
 XX (HINZ/) HINZMANN B.
 PA (HERM/) HERMANN K.
 PA (CAST/) HEIDEN CASTANOS-VELEZ B.
 PI Mennrich D, Brummendorf T, Heiden E, Hermann K, Kinnemann H, Rosenthal A, Pilarsky C,
 Li X, Roepcke S, Staub B, Hinzmann B,
 XX

RESULT 17
 ID DR N-PSDB; ADU06201.
 PT New nucleic acid, and derived proteins, useful for diagnosis of bronchial cancer and in screening for therapeutic and diagnostic agents.
 XX
 PS Claim 2: SEQ ID NO 914; 1381pp; German.
 XX
 CC This invention relates to a novel isolated nucleic acid associated with bronchial cancer comprising 489 defined sequences given in the specification. The invention may be useful for the production of compounds with a cytostatic activity through the inhibition of expression or activity of tumour-associated proteins. The novel DNA sequences and the proteins/peptides encoded by them are used for detecting bronchial cancer or determining the risk of developing it and to screen for specific binding partners of the DNA or protein sequences, where the binding partners are potentially useful as agents for treating or diagnosing bronchial cancer. The DNA or protein sequences can also be used for prognosis, detection of metastases and for secondary treatment (of tumours that have been stabilised or are no longer detectable). Detecting abnormal expression of the DNA sequences provides early diagnosis of bronchial cancers. The present sequence is that of a protein encoded by a novel bronchial cancer-associated human gene sequence of the invention.
 XX
 Sequence 766 AA:
 SQ

Query	Match	Score	Length	DB	Match	Score	Length	DB	Match	Score	Length	DB	
Qy	98	0%	3939	DB 8;	Qy	98	0%	3939	DB 8;	Qy	98	0%	3939
	Best Local Similarity	Pred. No.	0;		Best Local Similarity	Pred. No.	0;		Best Local Similarity	Pred. No.	0;		
	Matches 728;	Conservative	0;		Matches 728;	Conservative	0;		Matches 728;	Conservative	0;		
		Max mismatches	0;			Max mismatches	0;			Max mismatches	0;		
		Indels	0;			Indels	0;			Indels	0;		
		Gaps	0;			Gaps	0;			Gaps	0;		

Db 13 SRKTYTLDVYKNTYRKLKLYSLRWSDHELYKQENNLVYFNAEYGNSSVPLENSTDFDEF 72
 Db 39 SRKTYTLDVYKNTYRKLKLYSLRWSDHELYKQENNLVYFNAEYGNSSVPLENSTDFDEF 98
 Qy 73 GHSINDYDISPDGQFILLENYVKQWRSHTASYDLYDNLKROLTEERIPNTNTQYNTWS 132
 Db 99 GHSINDYDISPDGQFILLENYVKQWRSHTASYDLYDNLKROLTEERIPNTNTQYNTWS 158
 Qy 133 PVGHKLYAWWNNDDIVYKIEPLPSPTRITWCKEDITYNGITDWWVYBEEVFSAYSALWSP 192
 Db 159 PVGHKLYAWWNNDDIVYKIEPLPSPTRITWCKEDITYNGITDWWVYBEEVFSAYSALWSP 218
 Qy 193 NGTFLAYAQFDNTEVPLIYFSYSDSLOQPKTVRYPKRAGAVNPVKFPVNTDSLSS 252
 Db 219 NGTFLAYAQFDNTEVPLIYFSYSDSLOQPKTVRYPKRAGAVNPVKFPVNTDSLSS 278
 Qy 253 VTNATSIQITAPASMLGDHYLCDWTQERISLQWLRRIQYNSMDICDYDESSGRWN 312
 Db 279 VTNATSIQITAPASMLGDHYLCDWTQERISLQWLRRIQYNSMDICDYDESSGRWN 338
 Qy 313 CLVARQHIEMSTGTYWGRFRSEPHFTLDGNSFYKTIISNEGYRATICYQFDKDKDTFT 372
 Db 339 CLVARQHIEMSTGTYWGRFRSEPHFTLDGNSFYKTIISNEGYRATICYQFDKDKDTFT 398
 Qy 373 KGTWTETVIGIBALTSQDLYYTSNEYKGMGRNLYKIQLSDTYTCKVTCISCLNPERCOYYS 432
 Db 399 KGTWTETVIGIBALTSQDLYYTSNEYKGMGRNLYKIQLSDTYTCKVTCISCLNPERCOYYS 458
 Qy 433 VSFSKERAKYYQQLRCSGFPGLPLTYLHSVNDKGLRVEEDNSALDKMQLQVNPMSKQLDFII 492
 Db 459 VSFSKERAKYYQQLRCSGFPGLPLTYLHSVNDKGLRVEEDNSALDKMQLQVNPMSKQLDFII 518
 Qy 493 LNNETKFWYQMLPPHDKSKYKPLLLDVYAGPCSQADTVFRLNATYLASTENIVASF 552
 Db 519 LNNETKFWYQMLPPHDKSKYKPLLLDVYAGPCSQADTVFRLNATYLASTENIVASF 578
 Qy 553 DGRGSGYQGDKIMHA, INRRLGTFEVYDQEAFARQSMGFVDMRQVSYGTYWTSM 612
 Db 579 DGRGSGYQGDKIMHA, INRRLGTFEVYDQEAFARQSMGFVDMRQVSYGTYWTSM 638
 Qy 613 VLGSGSYVKCGIAVAPVSRWEYDSVTEYMGPLPTEDNLDHYTNSTMSRAENFKQV 672

PT Use of a CD26 composition, and a chemotherapeutic and/or a radiotherapeutic agent for e.g. inhibiting the cell growth, inducing cell cycle arrest, killing a cancer cell, treating cancer, or inducing tumor regression or tumor necrosis.

XX

CC The specification describes a CD26 composition which, in conjunction with the sensitivity of CD26 to the chemotherapeutic or radiotherapeutic agent, enhances the sensitivity of the cancer cell to the chemotherapeutic or radiotherapeutic agent. CD26 is a dipeptidyl peptidase IV (DPPIV). The CD26 composition of the invention is a topoisomerase II inhibitor. The CD26 composition of the invention is useful for inhibiting the growth of a cell, inducing cell cycle arrest in a cell, killing a cancer cell, potentiating the effect of a chemotherapeutic agent and/or a radiotherapeutic agent on a tumour cell, inducing or enhancing apoptosis of a cancer cell, treating cancer, or inducing tumour regression or tumour necrosis. The CD26 composition is further useful for increasing topoisomerase II expression in a cell, for activating an antigen-presenting cell, or for potentiating immune responses of an animal. The present sequence represents a CD26 protein, and is encoded by vectors which are used to produce compositions of the invention.

XX

SQ Sequence 766 AA;

Query Match 98.0%; Score 3939; DB 8; Length 766;

Best Local Similarity 100.0%; Pred. No. 0; Mismatches 0; Indels 0; Gaps 0; Matches 728; Conservative

Qy 13 SRKTYLTIDYLKNTYRLKLYSLRWSIDHEYLQKQENNLVFNAYCNSVLENSTFDEF 72
Db 39 SRKTYLTIDYLKNTYRLKLYSLRWSIDHEYLQKQENNLVFNAYCNSVLENSTFDEF 98

Qy 73 GHSINDYSISPGQFILLENYTVKQRHSSYTAQSYDIDLNKRQLITEERIPNNTQWTS 132
Db 99 GHSINDYSISPGQFILLENYTVKQRHSSYTAQSYDIDLNKRQLITEERIPNNTQWTS 158

Qy 133 PVGHKLAYVWNNDIYVKEPNLPSYRITWKGEDIYNGITDWWYBEEVFSAYSALWWSP 192
Db 159 PVGHKLAYVWNNDIYVKEPNLPSYRITWKGEDIYNGITDWWYBEEVFSAYSALWWSP 218

Qy 193 NGTFLAYAQNDTEVPLJEYSFYSDESLQYKPTVRYPKAGAVNPVTKFFVNTDSLSS 252
Db 219 NGTFLAYAQNDTEVPLJEYSFYSDESLQYKPTVRYPKAGAVNPVTKFFVNTDSLSS 278

Qy 253 VTNATSIQITAPASMLIGDHYLCDVTTATOBTRISLQMLRRRIONSYMDICDYDESSGRNN 312
Db 279 VTNATSIQITAPASMLIGDHYLCDVTTATOBTRISLQMLRRRIONSYMDICDYDESSGRNN 338

Qy 313 CLVARQHIEMSTGIGRFRPSBPHFTLGDNSPYKYLISNEGYRHICYFQIDKKCQDFIT 372
Db 339 CLVARQHIEMSTGIGRFRPSBPHFTLGDNSPYKYLISNEGYRHICYFQIDKKCQDFIT 398

Qy 373 KTWEVIGEALTSQDLYVYISNEVKGRGPKGRMLYKIQSLDTKTCIICLNPERCOYS 432
Db 399 KTWEVIGEALTSQDLYVYISNEVKGRGPKGRMLYKIQSLDTKTCIICLNPERCOYS 458

Qy 433 VSFSEKAEKYQOLRCGSGPGLPLYTLHSSYNDKGLRVLIEDNSALDKMLQVNQPSKCKLDFII 492
Db 459 VSFSEKAEKYQOLRCGSGPGLPLYTLHSSYNDKGLRVLIEDNSALDKMLQVNQPSKCKLDFII 518

Qy 493 LNETKFWYQMIIPPHFDKSKRCPYPLLYAGCSCQADTVPLNWATYLAESTENIIVASF 552
Db 519 LNETKFWYQMIIPPHFDKSKRCPYPLLYAGCSCQADTVPLNWATYLAESTENIIVASF 578

Qy 553 DGRGSGYCGDKIMHAINRRLGTFEVDQIEARQFSRMGFVDNKRRAIWGNSYGGTVSM 612
Db 579 DGRGSGYCGDKIMHAINRRLGTFEVDQIEARQFSRMGFVDNKRRAIWGNSYGGTVSM 638

Qy 613 VLGSGSGYFKCGTAVAPVSRWYEDSYVTERYMLPTEPDNLHYRNTSMRAENFKQV 672
Db 639 VLGSGSGYFKCGTAVAPVSRWYEDSYVTERYMLPTEPDNLHYRNTSMRAENFKQV 698

Qy 673 EYLILHGTTADDNVHQQSAQISKVALVYDGVDFQAMWYTDGDHGIASSTAHQHITYTMMSHF 732
Db 699 EYLILHGTTADDNVHQQSAQISKVALVYDGVDFQAMWYTDGDHGIASSTAHQHITYTMMSHF 758

Qy 733 IKQCFSLP 740
Db 759 IKQCFSLP 766

RESULT 14
ABMB0355 standard; protein; 766 AA.

ID ABMB0355
XX AC ABMB0355;
XX DT 18-NOV-2004 (first entry)
XX Tumour-associated antigenic target (TAT) polypeptide PRO80881, SEQ: 895.
XX Tumour-associated antigenic target; TAT; human; overexpression; cancer;
KW tumour; diagnosis; cell proliferative disorder; breast cancer;
KW colorectal cancer; lung cancer; ovarian cancer; liver cancer;
KW central nervous system cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; melanoma; leukaemia; hybridisation probe;
KW chromosome identification; chromosome mapping; gene mapping;
KW gene therapy; cytostatic.

Qy 99 Homo sapiens.
OS Homo sapiens.
XX PN WO2004030615-A2.
XX PD 15-APR-2004.
XX PP 29-SEP-2003; 2003WO-US028547.
XX PR 02-OCT-2002; 2002US-0414971P.
XX PA (GETH) GENENTECH INC.
XX PI Wu TD, Zhang Z, Zhou Y;
XX DR WPI; 2004-347921/32.
XX DR WPI; 2004-347921/32.
XX DR N-PSDB; ACN37733.
XX PS Claim 12; SEQ ID NO 895; 7273PP; English.

PT New tumor-associated antigenic target polypeptides and nucleic acids, useful in preparing a medicament for treating or detecting a proliferative disorder, e.g. breast, lung, colorectal, ovarian or prostate cancer or tumor.

PT The invention relates to human tumour-associated antigenic target (TAT) polypeptides, and their related nucleic acids. The TAT polypeptides are overexpressed in cancer tissues compared to normal tissues, and may thus serve as effective targets for the diagnosis and treatment of cancer in mammals. The invention also relates to nucleic acid and polypeptide sequences at least 80% identical to the TAT nucleic acids and polypeptides; expression vectors and host cells comprising a TAT nucleic acid, an antibody specific for a TAT polypeptide; fusion proteins comprising a TAT polypeptide; and methods and compositions for the treatment or diagnosis of cancer in mammals. TAT polypeptides, nucleic acids, antibodies, antagonists, binding molecules and compositions are useful for diagnosing or creating a cell proliferative disorder associated with increased TAT expression, particularly cancers such as breast cancer, colorectal cancer, lung cancer, ovarian cancer, liver cancer, bladder cancer, pancreatic cancer, cervical cancer, cancers of the central nervous system, melanoma and leukaemia. TAT nucleic acids may further be used as hybridisation probes, in chromosome and gene mapping, in chromosome identification and in gene therapy. The present sequence represents a TAT polypeptide of the invention

RESULT 12	Qy	193	NGTFLAYAQFNNDTEVPLIYSPYQFESLOYPKTIVRVPYKAGAVNPTVKEFVNTDSLSS	252
AD071612	Db	219	NGTFLAYAQFNNDTEVPLIYSPYQFESLOYPKTIVRVPYKAGAVNPTVKEFVNTDSLSS	278
ID AD071612 standard; protein; 766 AA.				
XX				
AC AD071612;	Qy	253	VTNATSIQITAPASMLIGDHLCVWTQERISIQLPKTIVRVPYKAGAVNPTVKEFVNTDSLSS	312
XX	Db	279	VTNATSIQITAPASMLIGDHLCVWTQERISIQLPKTIVRVPYKAGAVNPTVKEFVNTDSLSS	338
DT 26-AUG-2004 (first entry)				
XX				
DE Amino acid sequence of a human CD26 protein.	Qy	313	CLVARQHIEMSTGIVGRRPSEHFTLDGNSFVKKISNEGGYHICYFQIDKQDCTFIT	372
XX	Db	339	CLVARQHIEMSTGIVGRRPSEHFTLDGNSFVKKISNEGGYHICYFQIDKQDCTFIT	398
KW CD26; chemotherapeutic; radiotherapeutic; cancer; cell growth;				
KW dipeptidyl peptidase IV; DPPIV; topoisomerase II inhibitor;				
KW cell cycle arrest; tumour; tumour necrosis; immune response; human.				
XX	Qy	373	KGTIVVIGEITALTSPLYLYTISNEYKGMPGCRNLKYLQSPYTKVTCLSCLNPBRCQYYS	432
OS Homo sapiens.	Db	399	KGTIVVIGEITALTSPLYLYTISNEYKGMPGCRNLKYLQSPYTKVTCLSCLNPBRCQYYS	458
XX				
PN WO2004045497-A2.	Qy	433	VSPFSEKAKTYQLRCSPGPGLPLYLTHSSYNDKGFLAVLEDNSALDKMLQNYOMPSPKQLDFTI	492
XX	Db	459	VSPFSEKAKTYQLRCSPGPGLPLYLTHSSYNDKGFLAVLEDNSALDKMLQNYOMPSPKQLDFTI	518
PD 03-JUN-2004.	Qy	493	LNEKTFWYQMLPPIKPHFDKSKYKPYLLDVTAGPCQOKADTVFRLNATVYLASTENITIVASF	552
XX	Db	519	LNEKTFWYQMLPPIKPHFDKSKYKPYLLDVTAGPCQOKADTVFRLNATVYLASTENITIVASF	578
PF 15-MAY-2003; 2003WO-US015499.	Qy	553	DGRSGGYQCDKIMHAIRRLGTFPEVEDQLEAARFSKMGFVDNRKIAITMGWSYGYVTSM	612
XX	Db	579	DGRSGGYQCDKIMHAIRRLGTFPEVEDQLEAARFSKMGFVDNRKIAITMGWSYGYVTSM	638
PR 17-MAY-2002; 2002US-0381606P.	Qy	613	VLGSGSGVFKFCGTAIVAPYSPRWEYDSVYTERMLGPTPBDNLHYRNSTMWSRAENPKQV	672
XX	Db	639	VLGSGSGVFKFCGTAIVAPYSPRWEYDSVYTERMLGPTPBDNLHYRNSTMWSRAENPKQV	698
PA (TEXA) UNIV TEXAS SYSTEM.	Qy	673	EYLJLHGTTADDNIFQFQQSQIISKLLVDFQDAMWYTDDBHGASSTAHQHITTHMSHF	732
XX	Db	699	EYLJLHGTTADDNIFQFQQSQIISKLLVDFQDAMWYTDDBHGASSTAHQHITTHMSHF	758
PS Claim 23; Page 151-153; 182pp; English.	Qy	733	IKQCFSLP 740	
XX	Db	759	IKQCFSLP 766	
CC The specification describes a CD26 composition which, in conjunction with				
CC chemotherapeutic or radiotherapeutic agents, is used for the treatment				
CC and prevention of cancers. Expression of CD26 enhances the sensitivity of				
CC the cancer cell to the chemotherapeutic or radiotherapeutic agent; CD26				
CC is a dipeptidyl peptidase IV (DPPIV). The chemotherapeutic agent is a				
CC topoisomerase II inhibitor. The CD26 composition of the invention is				
CC useful for inhibiting the growth of a cell, inducing cell cycle arrest in				
CC a cell, killing a cancer cell, potentiating the effect of a				
CC chemotherapeutic agent and/or a radiotherapeutic agent on a tumour cell,				
CC inducing or enhancing apoptosis of a cancer cell, treating cancer, or				
CC inducing tumour regression or tumour necrosis. The CD26 composition is				
CC further useful for increasing topoisomerase II expression in a cell, for				
CC activating an antigen-presenting cell, or for potentiating immune				
CC responses of an animal. The present sequence represents a CD26 protein,				
CC and is encoded by vectors which are used to produce compositions of the				
CC invention.				
XX Sequence 766 AA;	OS			
XX	XX			
Query Match 98.0%; Score 3939; DB 8; Length 766;	PN	WO004045497-A2.		
Best Local Similarity 100.0%; Pred. No. 0;	XX			
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	PD	03-JUN-2004.		
Qy	13	SRKTYLTDLKNTYTRKLKLYSLRWTISDHEYLKLYKQENNTLVFNAYGNSSVFLENSTFDEF	72	PF 15-MAY-2003; 2003WO-US015499.
Db	39	SRKTYLTDLKNTYTRKLKLYSLRWTISDHEYLKLYKQENNTLVFNAYGNSSVFLENSTFDEF	98	XX 17-MAY-2002; 2002US-0381606P.
Qy	73	GHSINDYSSPQDGQTLLEYNYQWRSYTAISDYLANKRQLITERPIPNNTQWVWMS	132	XX (TEXA) UNIV TEXAS SYSTEM.
Db	99	GHSINDYSSPQDGQTLLEYNYQWRSYTAISDYLANKRQLITERPIPNNTQWVWMS	158	XX Dang NH, Morimoto C;
Qy	133	PVGHKLAYWNNDIYKIEPNLPSYRITWTGKEDIYNGITDWTWYEEFVPSAYSALWNSP	192	XX WP; 2004-420511/39.
Db	159	PVGHKLAYWNNDIYKIEPNLPSYRITWTGKEDIYNGITDWTWYEEFVPSAYSALWNSP	218	XX DR N-PSDB; AD071643.

Db	339	CLVARQHIEMTTGTGVRPRSEPHFTLDGNSPFYKLIISNEGRHICYFQIDKKDCTFFIT	398	PS XX	Claim 7; SEQ ID NO 730; 1731PP; English.
Qy	373	KGTWEVIGIBALTSDLYLISNEYKGMGPGRNLYKIQLSDTYTKTCLSCELNPERCQYS	432	CC	The invention relates to human PRO polypeptides and the polynucleotides encoding them. The polypeptides and polynucleotides are useful for treating and diagnosing immune related disorders in mammals. The immune related disorders include systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, systemic sclerosis, Sjogren's syndrome, vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, demyelinating diseases of the central or peripheral nervous system, demyelinating polyneuropathy, Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. This sequence represents a human PRO polypeptide of the invention.
Db	399	KGTWEVIGIBALTSDLYLISNEYKGMGPGRNLYKIQLSDTYTKTCLSCELNPERCQYS	458	CC	
Db	433	VSPSKERAKYYQOLRCSPGFLPLTYLSSYNDKGRLVLEDNSALDKMQLNQVQMPSKKLDFII	492	CC	
Qy	459	VSPSKERAKYYQOLRCSPGFLPLTYLSSYNDKGRLVLEDNSALDKMQLNQVQMPSKKLDFII	518	CC	
Db	493	VSPSKERAKYYQOLRCSPGFLPLTYLSSYNDKGRLVLEDNSALDKMQLNQVQMPSKKLDFII	518	CC	
Qy	519	LNETKFWYQMLPYPHDKSKKTPLLDLYVAGPCSQKADTYFLRLNATYLLASTENIVASP	552	CC	
Db	519	LNETKFWYQMLPYPHDKSKKTPLLDLYVAGPCSQKADTYFLRLNATYLLASTENIVASP	578	CC	
Qy	553	DGRGSGYQGDKIMHAIRNLCTFEVEDQIEAROFSKMGFVDNKGRIIAWGMNSGGYVTSM	612	CC	
Db	579	DGRGSGYQGDKIMHAIRNLCTFEVEDQIEAROFSKMGFVDNKGRIIAWGMNSGGYVTSM	638	CC	
Qy	613	VLGSGSCVFKGIAIVAPVSRMEYDSVTERYMGPLPTEDQAMYTDEDHGIASSTAHQIYTHMSP	672	Query Match Best Local Similarity Matches	98.0%; score 3939; DB 8; Length 766; 100.0%; Pred. No. 0; 0; Mismatches 0; Indels 0; Gaps 0;
Db	639	VLGSGSCVFKGIAIVAPVSRMEYDSVTERYMGPLPTEDQAMYTDEDHGIASSTAHQIYTHMSP	698	Qy	13 SRKTTLTDYLNTRNLKLYSLRWSLSDHEYLYKQENNVLVNAEGNSVYLENSTFDEF 72
Qy	673	YLLINGTADDNWHFOQAQIQLSKALYDVGDFQAMYTDEDHGIASSTAHQIYTHMSP	732	Db	39 SRKTTLTDYLNTRNLKLYSLRWSLSDHEYLYKQENNVLVNAEGNSVYLENSTFDEF 98
Db	699	YLLINGTADDNWHFOQAQIQLSKALYDVGDFQAMYTDEDHGIASSTAHQIYTHMSP	758	Qy	73 GHSINDYDISPDGQFILLENYVKQWRHSTTASYDLYDILNKRQLTBEERIPNNTOVWTWS 132
Qy	733	IKQCFSLP	740	Db	99 GHSINDYDISPDGQFILLENYVKQWRHSTTASYDLYDILNKRQLTBEERIPNNTOVWTWS 158
Db	759	IKQCFSLP	766	Qy	133 PVGHKLLAYWNNDIVYKIEPNLPSRITWICKEDIYNGITDWWYEEEVPSAYSALWSP 192
Db	159	PVGHKLLAYWNNDIVYKIEPNLPSRITWICKEDIYNGITDWWYEEEVPSAYSALWSP	218	Db	159 PVGHKLLAYWNNDIVYKIEPNLPSRITWICKEDIYNGITDWWYEEEVPSAYSALWSP 218
Qy	193	NGTFLAYAQFDTEPLIYFSYSDLSOFTKTVYRVPYKAGAVNPTVKFVNTDSLSS	252	Qy	193 NGTFLAYAQFDTEPLIYFSYSDLSOFTKTVYRVPYKAGAVNPTVKFVNTDSLSS
Db	219	NGTFLAYAQFDTEPLIYFSYSDLSQFPTKTVYRVPYKAGAVNPTVKFVNTDSLSS	278	Db	219 NGTFLAYAQFDTEPLIYFSYSDLSQFPTKTVYRVPYKAGAVNPTVKFVNTDSLSS
Qy	253	VTNATSIQTAPASMLIGDAYLCDYLTWATQERISLQWLRITQYNSYMDICDYDESSGRWN	312	Qy	253 VTNATSIQTAPASMLIGDAYLCDYLTWATQERISLQWLRITQYNSYMDICDYDESSGRWN
Db	279	VTNATSIQTAPASMLIGDAYLCDYLTWATQERISLQWLRITQYNSYMDICDYDESSGRWN	338	Db	279 VTNATSIQTAPASMLIGDAYLCDYLTWATQERISLQWLRITQYNSYMDICDYDESSGRWN
Qy	313	CLVARQHIEMTTGNGRFRSEPHFTLDGNSPFYKLIISNEGRHICYFQIDKKDCTFIT	372	Qy	313 CLVARQHIEMTTGNGRFRSEPHFTLDGNSPFYKLIISNEGRHICYFQIDKKDCTFIT 372
Db	339	CLVARQHIEMTTGNGRFRSEPHFTLDGNSPFYKLIISNEGRHICYFQIDKKDCTFIT	398	Db	339 CLVARQHIEMTTGNGRFRSEPHFTLDGNSPFYKLIISNEGRHICYFQIDKKDCTFIT 398
Qy	373	KGTWEVIGIAUTSDLYYISNEYKGMGPGRNLYKIQSDTTCVCLSCENPERCQYS	432	Qy	373 KGTWEVIGIAUTSDLYYISNEYKGMGPGRNLYKIQSDTTCVCLSCENPERCQYS
Db	399	KGTWEVIGIAUTSDLYYISNEYKGMGPGRNLYKIQSDTTCVCLSCENPERCQYS	458	Db	399 KGTWEVIGIAUTSDLYYISNEYKGMGPGRNLYKIQSDTTCVCLSCENPERCQYS
Qy	433	VSPSKERAKYYQOLRCSPGFLPLTYLSSNDKGLRVLBEDNSALDKMQLNQVOMPSKLLDFII	492	Qy	433 VSPSKERAKYYQOLRCSPGFLPLTYLSSNDKGLRVLBEDNSALDKMQLNQVOMPSKLLDFII 492
Db	459	VSPSKERAKYYQOLRCSPGFLPLTYLSSNDKGLRVLBEDNSALDKMQLNQVOMPSKLLDFII	518	Db	459 VSPSKERAKYYQOLRCSPGFLPLTYLSSNDKGLRVLBEDNSALDKMQLNQVOMPSKLLDFII 518
Qy	493	LNETKFWYQMLPPHDKSKKTPLLDYYAGPCSKQADTYFLRLNATYLLASTENIVASP	552	Qy	493 LNETKFWYQMLPPHDKSKKTPLLDYYAGPCSKQADTYFLRLNATYLLASTENIVASP
Db	519	LNETKFWYQMLPPHDKSKKTPLLDYYAGPCSKQADTYFLRLNATYLLASTENIVASP	578	Db	519 LNETKFWYQMLPPHDKSKKTPLLDYYAGPCSKQADTYFLRLNATYLLASTENIVASP
Qy	553	DGRGSGSCVFKGIAIVAPVSRMEYDSVTERYMGPLPTEDQAMYTDEDHGIASSTAHQIYTHMSP	612	Qy	553 DGRGSGSCVFKGIAIVAPVSRMEYDSVTERYMGPLPTEDQAMYTDEDHGIASSTAHQIYTHMSP
Db	579	DGRGSGYQGDKIMHAIRNLCTFEVEDQIEAROFSKMGFVDNKGRIIAWGMNSGGYVTSM	638	Db	579 DGRGSGYQGDKIMHAIRNLCTFEVEDQIEAROFSKMGFVDNKGRIIAWGMNSGGYVTSM
Qy	613	VLGSGSCVFKGIAIVAPVSRMEYDSVTERYMGPLPTEDQAMYTDEDHGIASSTAHQIYTHMSP	672	Qy	613 VLGSGSCVFKGIAIVAPVSRMEYDSVTERYMGPLPTEDQAMYTDEDHGIASSTAHQIYTHMSP
Db	639	VLGSGSCVFKGIAIVAPVSRMEYDSVTERYMGPLPTEDQAMYTDEDHGIASSTAHQIYTHMSP	698	Db	639 VLGSGSCVFKGIAIVAPVSRMEYDSVTERYMGPLPTEDQAMYTDEDHGIASSTAHQIYTHMSP
Qy	673	YLLINGTADDNHFQOSAQIQLSKALYDVGDFQAMYTDEDHGIASSTAHQIYTHMSP	732	Qy	673 YLLINGTADDNHFQOSAQIQLSKALYDVGDFQAMYTDEDHGIASSTAHQIYTHMSP
Db	699	YLLINGTADDNHFQOSAQIQLSKALYDVGDFQAMYTDEDHGIASSTAHQIYTHMSP	758	Db	699 YLLINGTADDNHFQOSAQIQLSKALYDVGDFQAMYTDEDHGIASSTAHQIYTHMSP
Qy	733	IKQCFSLP	740	Qy	733 IKQCFSLP
Db	759	IKQCFSLP	766	Db	759 IKQCFSLP

PT New crystal of dipeptidyl peptidase IV capable of analyzing its three-dimensional structure, useful for designing, identifying, evaluating or searching an effector of the dipeptidyl peptidase IV.

XX

PS Claim 3 : SEQ ID NO 2 ; 332pp ; English.

XX

The invention relates to a novel crystal of a dipeptidyl peptidase IV (DPIV) which is sufficient to ensure a resolution capable of analysing its three-dimensional structure up to the side chain level by X-ray crystallographic structural analysis. The crystal of the invention demonstrates immunomodulatory, antidiabetic, antiinflammatory, neuroprotective, antithyroid, antirheumatic, antiarthritic, anti-HIV and cytostatic activities and may be useful for providing a three-dimensional structural coordinate as the information for designing, identifying, evaluating or searching for an effector of the dipeptidyl peptidase IV. The effector may be useful as a modulatory agent of immune response and as a therapeutic or prophylactic agent for diabetes, inflammation, multiple sclerosis, Grave's disease, chronic rheumatoid arthritis, AIDS or cancer. The current sequence is that of the human full-length colon dipeptidyl peptidase IV (DPIV) protein of the invention.

XX

Sequence 766 AA:

Query Match 98.0%; Score 3939; DB 8; Length 766;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1.3 SRKTYLTIDYLKNTYRKLYSRWRISDPEYLKYQKENNLLVYNAEYGSVYLENSTDFEF 72
 Db 3.9 SRKTYLTIDYLKNTYRKLYSRWRISDPEYLKYQKENNLLVYNAEYGSVYLENSTDFEF 98
 Qy 7.3 GHSINDYSISPGQFQILLENTYKWRHSSATASYDIDYLNRQLITERIPNTNTQWMS 132
 Db 9.9 GHSINDYSISPGQFQILLENTYKWRHSSATASYDIDYLNRQLITERIPNTNTQWMS 158
 Qy 13.3 PVGHLKLAQVWNNDIYVKEPNLPSYRITWKGKDIYNGITDWWYBEBFVAYSALWWSP 192
 Db 15.9 PVGHLKLAQVWNNDIYVKEPNLPSYRITWKGKDIYNGITDWWYBEBFVAYSALWWSP 218
 Qy 19.3 NCTFLAYAQFDNTDPEVPLLEYSYSDDELYQPTCVTPYKPKAGAVNPVTKPFVNTDSLSS 252
 Db 21.9 NCTFLAYAQFDNTDPEVPLLEYSYSDDELYQPTCVTPYKPKAGAVNPVTKPFVNTDSLSS 278
 Qy 25.3 VTNATSIQITAPASMLIGDHYLCDVTTATQERISLQMLRRIQNYSTMDICDYDESSGRWN 312
 Db 27.9 VTNATSIQITAPASMLIGDHYLCDVTTATQERISLQMLRRIQNYSTMDICDYDESSGRWN 338
 Qy 31.3 CLVARQHLEMSTGIGWGRFBPHFTLQDGNSPYKISNEEYRHCYFQIDKDKCFT 372
 Db 33.9 CLVARQHLEMSTGIGWGRFBPHFTLQDGNSPYKISNEEYRHCYFQIDKDKCFT 398
 Qy 37.3 KTWEVIGTEALTSQDLYYISNBVKGMPGGRNLKYQLSDTKTVCLSCBLNPERCOYS 432
 Db 39.9 KTWEVIGTEALTSQDLYYISNBVKGMPGGRNLKYQLSDTKTVCLSCBLNPERCOYS 458
 Qy 43.3 VFSKKEAKYQOLRCSGPQLPLYKLYQLSDTKTVCLSCBLNPERCOYS 492
 Db 45.9 VFSKKEAKYQMLPPHFDKSKRKPILLDYYAGCQSQADTVPLNWATYLASTENIVASF 552
 Db 51.9 LNBTKEFWYQMLPPHFDKSKRKPILLDYYAGCQSQADTVPLNWATYLASTENIVASF 578
 Qy 55.3 DFRGSGYQDKIMHAINRRLGTFEVQDQIEARQFSRMGFVDNKRJAIWGMSYGGVTSM 612
 Db 57.9 DFRGSGYQDKIMHAINRRLGTFEVQDQIEARQFSRMGFVDNKRJAIWGMSYGGVTSM 638
 Qy 61.3 VLGSGSGYVFKCGIAAVPVSREYYDSVYTERMGLPAPEDNLHYNTMSRAENFKQV 672
 Db 63.9 VLGSGSGYVFKCGIAAVPVSREYYDSVYTERMGLPAPEDNLHYNTMSRAENFKQV 698
 Qy 67.3 BYLLIHGTDADDNVHFOQSAQISKALVQDGVDFQAMWYTEDDGHIASSTAHOHTYTMHF 732

Db 699 BYLLIHGTDADDNVHFOQSAQISKALVQDGVDFQAMWYTEDDGHIASSTAHOHTYTMHF 758
 PT
 PT
 XX

PS

Qy 733 IKQCFSLP 740
 Db 759 IKQCFSLP 766

XX

RESULT 9
 ADJ75313 ID ADJ75313 standard: protein; 766 AA.
 XX

AC ADJ75313;
 DT 20-MAY-2004 (first entry)
 XX

DE Marker gene related amino acid sequence SEQ ID NO:565.
 XX
 KW bronchial asthma; chronic obstructive pulmonary disease;
 KW respiratory epithelial cell; interleukin-13; respiratory; antiasthmatic;
 KW gene therapy; marker.
 XX

OS Homo sapiens.
 XX
 PN EP1384274-A2.
 XX

PD 03-MAR-2004.
 XX

PF 04-AUG-2003; 2003EP-00254857.
 XX
 PR 06-AUG-2002; 2002JP-00259312.
 PR 20-MAR-2003; 2003JP-0077212.
 XX

PA (GENO-) GENOX RES INC.

XX

PI Ohtani N, Sugita Y, Yamaya M, Kubo H, Nagai H, Izuohara K;
 XX
 DR WPI; 2004-193155/19.
 XX

PT Testing for bronchial asthma or chronic obstructive pulmonary disease by comparing the expression level of a marker gene in a biological sample from a subject with the expression level of the gene in a sample from a healthy subject.
 XX

Example 11; SEQ ID NO 565; 241pp; English.

XX

CC The present invention describes a method of testing for bronchial asthma or chronic obstructive pulmonary disease. The method comprises determining the expression level of a marker gene in a biological sample from a subject, comparing the expression level determined with the expression level of the marker gene in a biological sample from a healthy subject, and judging whether the subject has bronchial asthma or chronic obstructive pulmonary disease. The marker gene comprises: (a) a group of genes (S1) whose expression levels increase when respiratory epithelial cells are stimulated with interleukin-13; or (b) a group of genes (S2) whose expression levels decrease when stimulated with interleukin-13. Also described: (1) a reagent (I) for testing for bronchial asthma or chronic obstructive pulmonary disease; (2) a kit for screening for a candidate compound for a therapeutic agent to treat bronchial asthma or chronic obstructive pulmonary disease; (3) an animal model for bronchial asthma or chronic obstructive pulmonary disease; (4) an inducer that induces bronchial asthma in a mouse; (5) a method for producing an animal model for bronchial asthma or chronic obstructive pulmonary disease; (6) a therapeutic agent for bronchial asthma or chronic obstructive pulmonary disease, comprising the compound, a marker gene or an antisense nucleic acid corresponding to a portion of the marker gene, ribozyme, a polynucleotide that suppresses the expression of the gene through an RNAi effect or an antibody recognising a protein encoded by a marker gene; and (7) a DNA chip for testing for bronchial asthma or a chronic obstructive pulmonary disease, on which a probe has been immobilised to assay a marker gene. (1) has respiratory and antiasthmatic activities, and can be used in gene therapy. The method is useful for testing for or screening for a therapeutic agent for bronchial asthma or chronic obstructive pulmonary disease. The present

PF	13 -NOV-2002; 2002WO-US036810.	Db	219 NGTFLAYAQPNDTVEPLIEYSFSDBSLQYPKTVRVPYKAGAVANPTVKEPVNTDSLSS 278
XX		Qy	253 VTNATSIQITAPASMLIGDHYLCUTWATERISLQWLRQIYNSYMDICDYESSGRWN 312
PR	13 -NOV-2001; 2001US-035066P.	Db	279 VTNATSIQITAPASMLIGDHYLCUTWATERISLQWLRQIYNSYMDICDYESSGRWN 338
PR	21 -NOV-2001; 2001US-033244P.	Qy	313 CLVAQHIEINSTGIVGRFRPSBPHFTLDENSPYKISNPEGYHICYFQIDKQDCTFIT 372
PR	29 -NOV-2001; 2001US-033493P.	Qy	339 CLVAQHIEINSTGIVGRFRPSBPHFTLDENSPYKISNPEGYHICYFQIDKQDCTFIT 398
PR	03 -DEC-2001; 2001US-033534P.	Db	373 KGTWVIGEALTSQDLYTISNEYTKGMPGGRNLTKIQLSPYTKTCLSCLENPNCQYYS 432
PR	14 -DEC-2001; 2001US-0340316P.	Db	399 KGTWVIGEALTSQDLYTISNEYTKGMPGGRNLTKIQLSPYTKTCLSCLENPNCQYYS 458
PR	08 -JAN-2002; 2002US-034711P.	Qy	433 VSPSKRKYQLRCSGPGLPLTLYSSVNDKGLTLEDNSALDQMLQNMQPSKXLDLDFII 492
PR	10 -JAN-2002; 2002US-034724P.	Qy	459 VSPSKRKYQLRCSGPGLPLTLYSSVNDKGLTLEDNSALDQMLQNMQPSKXLDLDFII 518
PR	08 -FEB-2002; 2002US-035255P.	Db	493 LNEKTFWYQMLPMPHDKSKYPLDLYAGPCSKADTVFRLWATYLASTENIVASF 552
PR	13 -FEB-2002; 2002US-0356714P.	Db	519 LNEKTFWYQMLPMPHDKSKYPLDLYAGPCSKADTVFRLWATYLASTENIVASF 578
PR	20 -FEB-2002; 2002US-0359077P.	Qy	553 DGRSGSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVDNRKIAITGWSYGYXTSM 612
PR	29 -MAR-2002; 2002US-0368809P.	Db	579 DGRSGSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVDNRKIAITGWSYGYXTSM 638
PR	04 -APR-2002; 2002US-037010P.	Qy	613 VLGSGSGVFKCGIAYAPVSBMEYDTSVTERYMLPTPBDNLDDHYRNSTMMSRAENFKQV 672
PR	12 -APR-2002; 2002US-0372246P.	Db	639 VLGSGSGVFKCGIAYAPVSBMEYDTSVTERYMLPTPBDNLDDHYRNSTMMSRAENFKQV 698
PR	05 -JUN-2002; 2002US-0386614P.	Qy	673 BYLJLHGADDNIVFQQSOQSKYPLDLYAGPCSKADTVFRLWATYLASTENIVASF 732
PR	16 -JUL-2002; 2002US-0396639P.	Db	699 BYLJLHGADDNIVFQQSAQSKYPLDLYAGPCSKADTVFRLWATYLASTENIVASF 753
PR	22 -JUL-2002; 2002US-0397775P.	Qy	733 IKQCFSLP 740
PR	22 -JUL-2002; 2002US-0397845P.	Db	759 IKQCFSLP 766
PR	09 -SEP-2002; 2002US-0409450P.	Qy	RESULT 8
XX	(EOSB) - EOS BIOTECHNOLOGY INC.	Qy	ADJ83981
XX	Afar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevezi PA;	Db	ID ADJ83981 standard; protein; 766 AA.
XX	Mack DH, Murray R, Watson SR, Wilson KB, Zlotnik A;	XX	AC ADJ83981;
XX	DR WPI: 2003-468649/44.	XX	DT 06-MAY-2004 (first entry)
XX	N-PSDB; ADN39271.	XX	XX Human full-length colon dipeptidyl peptidase IV (DPPIV) protein.
PT	Determining the presence or absence of a pathological cell in a patient,	XX	XX crystal; protein co-ordinate data; dipeptidyl peptidase IV; DPPIV;
PT	useful for diagnosing, prognosing or treating cancer, comprises detecting	XX	XX immunomodulatory; anti-diabetic; anti-inflammatory; neuroprotective;
PT	a nucleic acid in a biological sample.	XX	XX anithyroid; anti-rheumatic; anti-arthritic; anti-HIV; cytostatic;
XX	PS Claim 12; SEQ ID NO 590; 1385pp; English.	XX	XX immune response; diabetes; inflammation; multiple sclerosis;
XX	CC The invention relates to nucleic acids and proteins (ADN38683-ADN40064)	XX	XX Grave's disease; chronic rheumatoid arthritis; AIDS; cancer; human;
CC	CC whose expression is upregulated or downregulated in specific cancers or	XX	XX colon; enzyme.
CC	CC other diseases such as angiogenic or fibrotic disorders, and to methods	XX	
CC	CC of determining the presence or absence of a pathological cell in a		
CC	CC patient by detecting a nucleic acid at least 80% identical to those of		
CC	CC the invention or by detecting a polypeptide of the invention. The		
CC	CC invention also relates to expression vectors and host cells comprising a		
CC	CC nucleic acid of the invention; antibodies which specifically bind a		
CC	CC polypeptide of the invention; use of such antibodies for drug targeting;		
CC	CC and methods of screening for modulators of activity or expression of the		
CC	CC polypeptides and nucleic acids. The nucleic acids, polypeptides,		
CC	CC antibodies and methods are useful for diagnosing, prognosing and treating		
CC	CC cancer and other conditions such as psoriasis, ischaemia, heart disease,		
CC	CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal		
CC	CC neovascularisation syndromes, scarring and uterine fibroids. They may		
CC	CC also be useful in wound healing and in contraception. The present		
CC	CC sequence represents a polypeptide of the invention.		
SQ	Sequence 766 AA:		
	Query Match 98.0%; Score 3939; DB 7; Length 766;		
	Best Local Similarity 100.0%; Pred. No. 0;	OS	
	Matches 728; Conservative 0; Mismatches 0; Indels 0; Gads 0;	XX	
Qy	13 SRKTYLTDLKNTYRKLKYSRWSLTSRDLHEYLKQENNTLVFNABYGNSSVLELENSTFDEF 72	PN	WO2004011640-A1.
Db	39 SRKTYLTDLKNTYRKLKYSRWSLTSRDLHEYLKQENNTLVFNABYGNSSVLELENSTFDEF 98	XX	
Qy	73 GHSINDYSISPDGQFILLEYNYKQWRSYTAIDYLNKROLITERIPNNTQWYTW 132	PD	05-FEB-2004.
Db	99 GHSINDYSISPDGQFILLEYNYKQWRSYTAIDYLNKROLITERIPNNTQWYTW 158	XX	28-JUL-2003; 2003WO-JP009523.
Qy	133 PVGHKLTAWNDIVKIEPNLPSRITWGTBLLINGITDWTWYEEBPSAYSALWSP 192	PR	29-JUL-2002; 2002US-0398761P.
Db	159 PVGHKLTAWNDIVKIEPNLPSRITWGTBLLINGITDWTWYEEBPSAYSALWSP 218	XX	(TANAKA) TANAKA SEIYAKU CO.
Qy	193 NGTFLAYAQPNDTVEPLIEYSFSDBSLQYPKTVRVPYKAGAVNPTVKEPVNTDSLSS 252	PA	PA
		PI	Hiramatsu H, Kyono K, Shima H, Sugiyama S;
		DR	DR WPT; 2004-156830/15.
		DR	N-PSDB; ADJ83980.
		XX	

73	GHSINDYSSIPDGQFILLENTVVKQRHSTASYDYLNRQLEERIPNTQWTS	132
29-JAN-2004	(revised)	
29-JAN-2004	(First entry)	
DB	Human Protein AAA52308, SEQ ID NO 12620.	
XX	Human; pain; neuronal tissue; gene therapy; spinal segmental nerve injury; chronic constriction injury; CCI; spared nerve injury; SNI; Chung.	
XX	Homo sapiens.	
XX	Unidentified.	
XX	WO2003016475-A2.	
27-FEB-2003.		
14-AUG-2002; 2002WO-US025765.		
14-AUG-2001; 2001US-0312147P.		
PR 01-NOV-2001; 2001US-0345382P.		
26-NOV-2001; 2001US-0333347P.		
XX	(GEHO) GEN HOSPITAL CORP.	
PA (FARB) BAYER AG.		
PA XXX	Woolf C, D'urso D, Befort K, Costigan M;	
XX	WPI: 2003-268312/26.	
XX	GENBANK; AAA52308.	
XX	New composition comprising two or more isolated polypeptides, useful for preparing a medicament for treating pain in an animal.	
XX	Example 1; Page: 1017pp; English.	
XX	The invention discloses a composition comprising two or more isolated rat or human polynucleotides or a polynucleotide which represents a fragment, derivative or allelic variation of the nucleic acid sequence. Also claimed are a vector comprising the novel polynucleotide, a host cell comprising the vector, a method for identifying a nucleotide sequence which is differentially regulated in an animal subjected to pain and a kit to perform the method, an array, a method for identifying an agent that increases or decreases the expression of the polynucleotide sequence of a first animal that is differentially expressed in neuronal tissue of a first animal subjected to pain, a method for identifying a compound which regulates the expression of a polynucleotide sequence which is differentially expressed in an animal subjected to pain, a method for identifying a compound that regulates the activity of one or more of the polynucleotides, a method for producing a pharmaceutical composition, a method for identifying a compound or small molecule that regulates the activity in an animal of one or more of the polypeptides given in the specification, a method for identifying a compound useful in treating pain and a pharmaceutical composition comprising the one or more polypeptides or their antibodies. The polynucleotide or the compound that modulates its activity is useful for preparing a medicament for treating pain (e.g. spinal segmental nerve injury (Chung), chronic constriction injury (CCI) and spared nerve injury (SNI) in an animal (e.g. gene therapy). The sequence presented is a human protein (described in Table 3 of the specification) which is differentially expressed during pain. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic form directly from WIPO at ftp://wipo.int/pub/published_pct_sequences.	
XX	Sequence 766 AA;	
XX	Score 3939; DB 7; Length 766;	
XX	Best Local Similarity 100.0%; Pred. No. 0;	
XX	Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
XX	SQ 13 SRKTYLTDYLKNTYRKLYSURWISDHEYLQKQENNLLVNAEYGNSSVPLENSTFDEF 72	
XX	SRKTYLTDYLKNTYRKLYSURWISDHEYLQKQENNLLVNAEYGNSSVPLENSTFDEF 98	
Db	RESULT 7	
Db	ADN39272 standard; protein; 766 AA.	
XX	ID ADN39272	
XX	AC ADN39272;	
XX	DT 17-JUN-2004 (first entry)	
XX	DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:590.	
XX	KW Human; differential expression; cancer; angiogenic disorder;	
XX	KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;	
XX	KW inflammatory disease; autoimmune disease;	
XX	KW retinal neovascularization syndrome; scarring; uterine fibroid;	
XX	KW detection; diagnosis; prognosis; drug screening; drug targeting;	
XX	KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;	
XX	KW pulmonary; gene therapy; vaccine.	
XX	OS Homo sapiens.	
XX	PN WO2003042661-A2.	
XX	XX 22-MAY-2003.	

3.73	KGTVIEWIGIBALTS'DYLYTISNEYKGMPCGRNLYKIQIQLSDYTKVTCUCLSCELNPERCOYYS	432
3.99	KGTVIEWIGIBALTS'DYLYTISNEYKGMPCGRNLYKIQIQLSDYTKVTCUCLSCELNPERCOYYS	458
4.33	VSPFKEAKYIQLRCSGPGLPLTYLTHSSYNDKGILRVLDEQNSALDKMLQNLQVQNPFSKQLDFFI	492
4.59	VSPFKEAKYIQLRCSGPGLPLTYLTHSSYNDKGILRVLDEQNSALDKMLQNLQVQNPFSKQLDFFI	518
4.93	LNETKFWYQOMILPPIHFDKSKKPYPLLLDYAGPCSKQADTVPLNWATYLAESTENITYASF	552
5.19	LNETKFWYQOMILPPIHFDKSKKPYPLLLDYAGPCSKQADTVPLNWATYLAESTENITYASF	578
5.53	DGRSSGYQGDKIMHAIRNRLGTPEVEDQIEARQFSKNGFDVNKRRAIWGMSYGGVTSM	612
5.79	DGRSSGYQGDKIMHAIRNRLGTPEVEDQIEARQFSKNGFDVNKRRAIWGMSYGGVTSM	638
6.13	VLGGSGSVPKCGIAVAPYRSWYEYDSYTYERTMGLPTPEDNLDHYRNSTNMSRAENFKQV	672
6.39	VLGGSGSVPKCGIAVAPYRSWYEYDSYTYERTMGLPTPEDNLDHYRNSTNMSRAENFKQV	698
6.73	EYLJLHGADDNYFQOSAQIISKALVVDGVDFQAMWTTDEDGIASTAHQHITYTMSHF	732
6.99	EYLJLHGADDNYFQOSAQIISKALVVDGVDFQAMWTTDEDGIASTAHQHITYTMSHF	758
7.33	IKCQFSLP	740
7.59	IKCQFSLP	766

BRUNSWICK

RESULTS
ADD27855 ADD27855 standard; protein; 766 AA.
XX ADD27855
AC XX ADD27855;
XX 15-JAN-2004 (first entry)

Homo sapiens.

03165489-A1.
EP-2003.
OV-2001; 2001US-00993959.
EB-2001; 2001US-00794236.
A-) BMRA CORP BV.
Lacroix J., Monchaux B., Lachmann B.

2003-811386/76. treatment of patient for mucosal inflammation associated with rhinitis or sinusitis involves intranasally administering peptide that scores at Xaa-Pro sequences or agent inhibiting binding of Sp to brinilin 1 receptor.

CCW 2025 Disclosure; SEQ ID NO 1; 14pp; English.

The present invention relates to a method of treating a patient for mucosal inflammation associated with rhinitis and/or sinusitis. The method comprises intranasally administering to the patient a peptidase that cleaves at Xaa-Pro sequences or an agent that inhibits the binding of substances to the mucin. The invention also relates to a pharmaceutical composition comprising a peptidase or an agent that inhibits the binding of substances to the mucin, a mucin, and a pharmaceutically acceptable carrier.

Sequence 766 AA:						
	Query Match Matches	Match Similarity	Score 0;	DB 7; Pred. No. 0;	Length 98.0*;	Peptidase IV
Qy	13	SRKTYTLDLKYTYRLKLYSLRWSIDBLYKOBNNILVFNAYGNSSYPLENSPTDPF	98.0*	939; 0;	DB 7;	Length 766;
Db	39	SRKTYTLDLKYTYRLKLYSLRWSIDBLYKOBNNILVFNAYGNSSYPLENSPTDPF	98.0*	939; 0;	DB 7;	Length 766;
Qy	73	GHISINDTISIPDQFILLBYNTYKQWRHSYTASTDIYDANKRQLTTEIRPNNNTQWVTS	98.0*	13; 0;	DB 7;	Length 766;
Db	99	GHISINDTISIPDQFILLBYNTYKQWRHSYTASTDIYDANKRQLTTEIRPNNNTQWVTS	98.0*	13; 0;	DB 7;	Length 766;
Qy	133	PVGHKLAQYWNNNDIYKVKIEPNLPSYRITWTKGEDIYINGITDWMYEEEVPSAYSAWMSP	98.0*	19; 0;	DB 7;	Length 766;
Db	159	PVGHKLAQYWNNNDIYKVKIEPNLPSYRITWTKGEDIYINGITDWMYEEEVPSAYSAWMSP	98.0*	19; 0;	DB 7;	Length 766;
Qy	193	NGTFLAYAQFNDTBVPLIBYSFVPSDESLSQYPKTVRVPYKAGANVPTVKEFVNTDSSLSS	98.0*	25; 0;	DB 7;	Length 766;
Db	219	NGTFLAYAQFNDTBVPLIBYSFVPSDESLSQYPKTVRVPYKAGANVPTVKEFVNTDSSLSS	98.0*	27; 0;	DB 7;	Length 766;
Qy	253	VTNATSIQITAPASMLGHDYLCDDTVWATQBRISLQWLRQIQTNSVMDICDYZDSSGRWN	98.0*	31; 0;	DB 7;	Length 766;
Db	279	VTNATSIQITAPASMLGHDYLCDDTVWATQBRISLQWLRQIQTNSVMDICDYZDSSGRWN	98.0*	31; 0;	DB 7;	Length 766;
Qy	313	CLVARQHIEMSTTGWGRFRPSPHFTLDGNSPEVKIIISNEGYHICYQIDKQDCTPIT	98.0*	37; 0;	DB 7;	Length 766;
Db	339	CLVARQHIEMSTTGWGRFRPSPHFTLDGNSPEVKIIISNEGYHICYQIDKQDCTPIT	98.0*	37; 0;	DB 7;	Length 766;
Qy	373	KGTWEVIGBALTSDVLYISNEYKKGMPGGRNLVYKIQSLQSDYTCTVCLSCELNPBCQYYS	98.0*	43; 0;	DB 7;	Length 766;
Db	399	KGTWEVIGBALTSDVLYISNEYKKGMPGGRNLVYKIQSLQSDYTCTVCLSCELNPBCQYYS	98.0*	45; 0;	DB 7;	Length 766;
Qy	433	VFSFSEAKYQYRCSGIGLPLTHSSYNDKGJLRVLEDSALDMLQNYQMPSPCLQDFTI	98.0*	49; 0;	DB 7;	Length 766;
Db	459	VFSFSEAKYQYRCSGIGLPLTHSSYNDKGJLRVLEDSALDMLQNYQMPSPCLQDFTI	98.0*	49; 0;	DB 7;	Length 766;
Qy	493	LNETKPYQMLLPPHFKSKYPLIJDYAGPCSKQADTVFRLWATYLASTENIVASP	98.0*	55; 0;	DB 7;	Length 766;
Db	519	LNBTKPYQMLLPPHFKSKYPLIJDYAGPCSKQADTVFRLWATYLASTENIVASP	98.0*	57; 0;	DB 7;	Length 766;
Qy	553	DGRGSGYQGDKIMHAINRRLGTFEVQDQEIAQRFSKONGFVDNKRIALWGMWSGGYVTSM	98.0*	61; 0;	DB 7;	Length 766;
Db	579	DGRGSGYQGDKIMHAINRRLGTFEVQDQEIAQRFSKONGFVDNKRIALWGMWSGGYVTSM	98.0*	63; 0;	DB 7;	Length 766;
Qy	613	VLGSGSCVFKCGIAVAFVSRRWYYDSYTERMGLPTBNDLHYRNSTMRSLENPKQV	98.0*	67; 0;	DB 7;	Length 766;
Db	639	VLGSGSCVFKCGIAVAFVSRRWYYDSYTERMGLPTBNDLHYRNSTMRSLENPKQV	98.0*	69; 0;	DB 7;	Length 766;
Qy	673	EYLLIHTGADDNVHFQOSAQ1SKALVQDGVDFQAMWYTDDEHGJASSTAHQHITYTHMSHF	98.0*	73; 0;	DB 7;	Length 766;
Db	699	EYLLIHTGADDNVHFQOSAQ1SKALVQDGVDFQAMWYTDDEHGJASSTAHQHITYTHMSHF	98.0*	75; 0;	DB 7;	Length 766;
Qy	733	IKQCPSLP 740	98.0*	76; 0;	DB 7;	Length 766;
Db	759	IKQCPSLP 766	98.0*	76; 0;	DB 7;	Length 766;

Matches	728: Conservative	0: Mismatches	0: Indels	0: Gaps	0: OS
Qy	13 SRKTYLTLYKNTYTRKLKYSLRMISDHFLYKQENNIIVNARYGNSVPLLENSTDFP	72			XX
Db	39 SRKTYLTLYKNTYTRKLKYSLRMISDHFLYKQENNIIVNARYGNSVPLLENSTDFP	98			PN
Qy	73 GHSINDYSISPDGQFILLYKQWRRHSTASYDIDLNRQLITEEIPNNTQWVTS	132			XX
Db	99 GHSINDYSISPDGQFILLYKQWRRHSTASYDIDLNRQLITEEIPNNTQWVTS	158			PD 25-OCT-2001.
Qy	133 PVGHKLAYTWNNDIYVKKRBNLPSRITTGKEDIYNGTIDWYBEEFVSAYSALWNSP	192			PF 11-APR-2001; 2001W0-US040483.
Db	159 PVGHKLAYTWNNDIYVKKRBNLPSRITTGKEDIYNGTIDWYBEEFVSAYSALWNSP	218			PR 18-APR-2000; 2000US-0197508P.
Qy	193 NGTFLAYAQENDTEVPLIYSPSDESLOKPTKTRVPKAGAVNPTKPFVNTDLS	252			XX
Db	219 NGTFLAYAQENDTEVPLIYSPSDESLOKPTKTRVPKAGAVNPTKPFVNTDLS	278			PA (MILL-) MILLENIUM PHARM INC.
Qy	253 VTNATSIQTTAPASMLIGHYRCDVTTWQERISQWLRQIYNTQVMDTCDYDESSGRW	312			PA, Williamson M;
Db	279 VTNATSIQTTAPASMLIGHYRCDVTTWQERISQWLRQIYNTQVMDTCDYDESSGRW	338			WPI: 2002-034153/04.
Qy	313 CLVARQHLEMSTGNGWGRPRPSBEPHTJDCNSFYKLNISBEGYTHICFOIDKKDCTFT	372			XX
Db	339 CLVARQHLEMSTGNGWGRPRPSBEPHTJDCNSFYKLNISBEGYTHICFOIDKKDCTFT	398			PT New polypeptides 21953, member of human prolyl oligopeptidase family, useful as diagnostic targets and therapeutic agents for controlling
Qy	373 KGTMEVIGEALTSVDLYTISNEYKGMPCGRNLKYKIQLSDYTKVTCLSCELNPERCQTS	432			PT cancer, lymphoma and leukemia.
Db	399 KGTMEVIGEALTSVDLYTISNEYKGMPCGRNLKYKIQLSDYTKVTCLSCELNPERCQTS	458			XX
Qy	433 VSFSKEAKTYQLRSGPGLPLYTHISSYNDKGILRVLBDSALDKMLQNQMPSKKLDFI	492			PT Disclosure; Fig 3; 121pp; English.
Db	459 VSFSKEAKTYQLRSGPGLPLYTHISSYNDKGILRVLBDSALDKMLQNQMPSKKLDFI	518			XX
Qy	493 LNFTKFWYCMILPPHFDKSKYKPLDLYVAGPCSQAKADTYFLRNWATYLASTENIVASF	552			XX
Db	519 LNFTKFWYCMILPPHFDKSKYKPLDLYVAGPCSQAKADTYFLRNWATYLASTENIVASF	578			CC This invention relates to an isolated 21953 human prolyl oligopeptidase.
Qy	553 DGRGSGYQDKIMEAIRNLGTFPEVDQEAAROFKNGFVDNKRIAITGWSYGGVTSM	612			CC Which is cytotropic, antiarthritic, neuroprotective, antithrombotic,
Db	579 DGRGSGYQDKIMEAIRNLGTFPEVDQEAAROFKNGFVDNKRIAITGWSYGGVTSM	638			CC antithyroid, dermatological, antiobiotic, antipsoriasis, anticonvulsant, ophthalmological, antiinflammatory, nootropic, antiparkinsonian,
Qy	613 VLGSGSGVTPKCGIAVAPVSRWEYDSVTERYGMGLPTPBDNLDTYRNSTMRSAYENFKQV	672			CC anticonvulsant, gynaecological, vasotropin, antiasthmatic, antihypertensive, and metabolic in its action. Users include
Db	639 VLGSGSGVTPKCGIAVAPVSRWEYDSVTERYGMGLPTPBDNLDTYRNSTMRSAYENFKQV	698			CC antatherosclerotic, anorectic and metabolic in its action. Users include
Qy	673 EYLLIHGTAADDNHFQOQSQISKALVDVSDFOAMWYTDHGTASSTAHQIYTHMHSF	732			CC gene therapy, expression or activity of 21953 protein modulator, used in
Db	699 EYLLIHGTAADDNHFQOQSQISKALVDVSDFOAMWYTDHGTASSTAHQIYTHMHSF	758			CC use for identifying a compound which binds to it and can be used in
Qy	733 IKQCFSLP 740				CC preventing, treating or detecting a cellular proliferative or
Db	759 IKQCFSLP 766				CC differentiative disorder. The 21953 molecules can act as novel diagnostic
Qy	RESULT 4				CC targets and therapeutic agents for controlling disorders associated with
Db	AACT8411 standard; protein; 766 AA.				CC the aberrant activity or degradation of peptide hormones e.g., disorders
Qy	AAG78411;				CC associated with cell differentiation and proliferation such as cancer,
Db	12-APR-2002 (first entry)				CC immune function, reproductive, neurological and cardiovascular function.
Qy	Human dipeptidyl peptidase IV amino acid sequence.				CC The 21953 molecules are thus useful for treating and preventing cellular
Db	21953 prolyl oligopeptidase; antibody; proline; endopeptidase; cancer;				CC proliferative and differentiative disorders, haemopoietic neoplastic
Qy	cardiovascular disease; autoimmune disease; atopic allergy;				CC disorders, immune disorders such as autoimmune diseases, diabetes
Db	neuronal disorder; vascular disorder; prostate disorder; cytostatic;				CC mellitus, arthritis, multiple sclerosis, asthma, Grave's disease,
Qy	diabetes mellitus; arthritis; multiple sclerosis; asthma;				CC metabolism or pain disorders, demyelinating diseases, vascular disorders and
Db	Grave's disease; neuronal disorder; demyelinating disease;				CC sequence of human dipeptidyl peptidase IV
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Qy	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase; cancer;				XX
Db	321953 polyproline dipeptidyl peptidase; antibody; proline; endopeptidase;				

FT	Region	552..766 /label= C-terminal region of extracellular domain /note= "1 N-linked glycosylation site & 1 catalytic site"	Qy	433 VSPSKPEAKTYQLRCSPGGLPYTLHSSVNDKGRLRVEDNSALDKMLQNVQMPSPCKLDPFI 492
FT	Active-site	627..631 /label= active site of serine protease/esterase /note= "fits the consensus sequence GX5GX"	Db	459 VSPSKPEAKTYQLRCSPGGLPYTLHSSVNDKGRLRVEDNSALDKMLQNVQMPSPCKLDPFI 518
FT			Qy	493 LNTEKREWYQMLPHEFDKSKYPLDLYVAGPCSKQADTVPLNATYLASTENIVASV 552
FT			Db	519 LNTEKREWYQMLPHEFDKSKYPLDLYVAGPCSKQADTVPLNATYLASTENIVASV 578
XX	WO9316102-A1.		Qy	553 DGRGSGYQGDKIMAHAINRRLGTFEVDQIARQFSKMGFYDNDKRIAIWGSYGVYTM 612
XX	PD 19-AUG-1993.		Db	579 DGRGSGYQGDKIMAHAINRRLGTFEVDQIARQFSKMGFYDNDKRIAIWGSYGVYTM 638
XX	PF 09-APR-1992;	92WO-US002892.	Qy	613 VLGSGSGVFKCGIAYAPVSMWYDSVYTERMGLPTBDNLHVNSTWSRAENFKQV 672
XX	PR 06-FEB-1992;	92US-00832211.	Db	639 VLGSGSGVFKCGIAYAPVSMWYDSVYTERMGLPTBDNLHVNSTWSRAENFKQV 698
PA	(DAND) DANA FARBER CANCER INST INC.		Qy	673 EYLILHGTDADNVHFQSAQISKALVDGVDFQAMWYTEDDHGIASSTAHOHYTMSHF 732
XX	PI Morimoto C, Schlossman SP, Tanaka T;		Db	699 EYLILHGTDADNVHFQSAQISKALVDGVDFQAMWYTEDDHGIASSTAHOHYTMSHF 758
XX	DR WPI: 1993-272827/34.		Qy	733 IKQCFSLP 740
XX	DR N-PSDF; AAC046083.		Db	759 IKQCFSLP 766
FT	Polypeptide fragments of CD26 - are capable of disrupting binding of CD45 and CD26 and thus interfering with T-cell activation.		RESULT 3	
FT	PS Disclosure; Page 39-43; 73pp; English.		ABB08991	ABB08991 standard; protein; 766 AA.
XX	XX		1D	ABB08991 standard; protein; 766 AA.
CC	CC		XX	XX
CC	CC		AC	ABB08991;
CC	CC		XX	XX
CC	CC		DT	19-JUN-2002 (first entry)
CC	CC		XX	XX
CC	CC		DE	Human dipeptidyl peptidase IV.
CC	CC		XX	XX
CC	CC		KW	Human; dipeptidyl peptidase IV; antiasthmatic; antiallergic; antiinflammatory.
CC	CC		XX	XX
CC	CC		OS	Homo sapiens.
CC	CC		XX	XX
CC	CC		PN	US6337069-B1.
CC	CC		XX	XX
CC	CC		PD	08-JAN-2002.
CC	CC		PP	28-FEB-2001; 2001US-00794236.
CC	CC		XX	XX
CC	CC		PR	28-FEB-2001; 2001US-00794236.
CC	CC		XX	XX
CC	CC		PA	(BMRA-) BMRA CORP BV.
CC	CC		XX	XX
CC	CC		PI	Grouzmann E, Lacroix J, Monod M;
CC	CC		XX	XX
CC	CC		DR	WPI; 2002-163235/21.
CC	CC		XX	XX
CC	CC		PS	Disclosure; Col 9-14; 13pp; English.
CC	CC		XX	XX
CC	CC		PT	Treating a patient for mucosal inflammation associated with rhinitis, sinusitis or both, by intranasally administering a peptidase that cleaves at Xaa-Pro sequences, to the patient.
CC	CC		PT	Thus invention relates to the treating of a patient for mucosal inflammation associated with rhinitis or sinusitis, comprising intranasally administering a peptidase. The peptidase is considered antiasthmatic, antiallergic and antiinflammatory in its action. The peptidase cleaves at Xaa-Pro sequences and is useful for treating a patient for mucosal inflammation associated with rhinitis or sinusitis, which is the result of allergies or asthma. This sequence represents human dipeptidyl peptidase IV
CC	CC		XX	XX
CC	CC		Sequence 766 AA;	Sequence 766 AA;
Qy	Query Match 98.0%; Score 3939; DB 2; Length 766;		Qy	133 PVGHKLAYWVNDIYTKEPNLPSRITWTGKEDIYTNGITDWWYEEFVSAYSLWNSP 192
Qy	Best Local Similarity 100.0%; Pred. No. 0;		Db	159 PVGHKLAYWVNDIYTKEPNLPSRITWTGKEDIYTNGITDWWYEEFVSAYSLWNSP 218
Matches 728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			Qy	193 NGTFIAYAQFDNTEVPLIEFSYSDLSLQFPTKTVRVPYKAGAVNPTKEFVNTDSLSS 252
			Db	219 NGTFIAYAQFDNTEVPLIEFSYSDLSLQFPTKTVRVPYKAGAVNPTKEFVNTDSLSS 278
			Qy	253 VTNATSIQITAPASMLGHDYLCDTWATQRISLQLRQHNTSYMDICDYSSEGRNN 312
			Db	279 VTNATSIQITAPASMLGHDYLCDTWATQRISLQLRQHNTSYMDICDYSSEGRNN 338
			Qy	313 CLVAROHLEMSTTGWGRFPESEPHLTDNSPSYKIIISNBERGYRICYFQIDKDCTFT 372
			Db	339 CLVAROHLEMSTTGWGRFPESEPHLTDNSPSYKIIISNBERGYRICYFQIDKDCTFT 398
			Qy	373 KGTWEVIGTIBAITSQDLYIISNEYKGMPGGRNLYKIQSLDSDYTKTCLSCLNPERCQYYS 432
			Db	399 KGTWEVIGTIBAITSQDLYIISNEYKGMPGGRNLYKIQSLDSDYTKTCLSCLNPERCQYYS 458
			Query Match 98.0%; Score 3939; DB 5; Length 766;	Query Match 100.0%; Score 3939; DB 5; Length 766;
			Best Local Similarity 100.0%; Pred. No. 0;	Best Local Similarity 100.0%; Pred. No. 0;

98	1002	24.9	988	4	ABB65641	Drosophil	Db
99	998	24.8	775	9	ADY51819	T. rubrum	Qy
100	987	24.6	771	2	AAW89389	Aspergillus	Db
ALIGNMENTS							
RESULT 1							
ARR51612							
ID	AAR54612	standard; protein;	759	AA.			
XX							
AC	AAR51612;						
XX							
DT	25-MAR-2003	(revised)					
DT	09-DEC-1994	(First entry)					
DB	Delta3-9	CD26.					
XX							
KW	T cell activation antigen; CD26; analogues; deletion; soluble;						
KW	signal peptide; immune-stimulating; response-stimulating; AIDS;						
KW	immunosuppression; AIDS-related complex.						
XX							
OS	Homo sapiens.						
XX							
PH		Location/Qualifiers					
FT	Misc-difference 2..3						
FT	/note= "Position of delta3-9 deletion"						
XX							
PN	WO9409132-A1.						
XX							
PD	28-APR-1994.						
XX							
PP	19-AUG-1993;	93W0-US007923.					
XX							
PR	21-AUG-1992;	92US-00934162.					
XX							
PA	(DAND) DANA FARBER CANCER INST INC.						
XX							
PI	Morimoto C, Schlossman S, Tanaka T;						
XX							
DR	WPI: 1994-151317/18.						
XX							
PT	Polypeptide fragments and analogues of CD26 and encoding nucleic acid -						
PT	useful for stimulating immune response, e.g. for treatment of AIDS to						
PT	counteract immunosuppressive drug, and as vaccine adjuvant.						
XX							
PS	Claim 3: Page 49-52; 85pp; English.						
XX							
CC	The sequences given in AAR54612-14 represent analogues of the human T						
CC	cell activation antigen CD26 which have internal deletions. The analogues						
CC	pref. lack residues 3-9 or 24-34. These analogues are soluble under						
CC	physiological conditions and lack enough amino acid residues to render						
CC	them susceptible to cleavage by signal peptidase. The peptide fragments						
CC	and analogues are useful as immune or response-stimulating therapeutics,						
CC	eg. they may be used for treatment of disease conditions characterised by						
CC	immunosuppression, eg. AIDS or AIDS-related complex, other virally or						
CC	environmentally-induced conditions, and certain congenital immune						
CC	deficiencies. The peptides can be employed to increase immune function						
CC	which has been impaired by use of immunosuppressive drugs, such as certain						
CC	chemotherapeutic drugs. (Updated on 25-MAR-2003 to correct PN field.)						
SQ	Sequence 759 AA;						
XX							
Query Match	98.0%;	Score 3939;	DB 2;	Length 759;			
Best Local Similarity	100.0%;	Pred. No. 0;	Mismatches 0;	Indels 0;	Gap 0;		
Matches	728;	Conservative					
Qy	13 SRKTYTLDLKYTYRLKLYSLRWISEDEHYLKQENNLVFAEYGNSSVPLENSTDEF	72					
Db	32 SRKTYTLDLKYTYRLKLYSLRWISEDEHYLKQENNLVFAEYGNSSVPLENSTDEF	91					
Qy	73 GHSINDYSISPDQFILENYVKQMRHSYTAISYDYLNLKQLITERIPINTQWTS	132					

Result No.	Score	Query Match	Length	DB ID	Description
1	3.939	98.0	759	2 AAR54612	Aar54612 Delta3-9
2	3.939	98.0	766	2 AAR40509	Aar40509 Sequence
3	3.939	98.0	766	5 ABB08991	Abb08991 Human dip
4	3.939	98.0	766	5 AAG78417	Aag78417 Human dip
5	3.939	98.0	766	7 ADD27855	Add27855 Human dip
6	3.939	98.0	766	7 ADD46334	Add46334 Human Pro
7	3.939	98.0	766	7 ADN32972	Adn32972 Cancer/ an
8	3.939	98.0	766	8 ADJ83981	Adj83981 Human ful
9	3.939	98.0	766	8 ADJ75313	Adj75313 Marker ge
10	3.939	98.0	766	8 ADO1398	Ado1398 Human PRO
11	3.939	98.0	766	8 ADO19806	Ado19806 Human PRO
12	3.939	98.0	766	8 ADO71612	Ado71612 Amino aci
13	3.939	98.0	766	8 ADO71644	Ado71644 Amino aci
14	3.939	98.0	766	8 ABM80355	Abm80355 Tumour-as
15	3.939	98.0	766	8 ADP54458	Adp54458 Human PRO
16	3.939	98.0	766	8 ADU6688	Adu6688 Novel cel
17	3.939	98.0	766	8 ADV25225	Adv25225 Human dip
18	3.939	98.0	766	9 ADY15161	Ady15161 PRO polyp
19	3.939	98.0	766	9 ADY15580	Ady15580 PRO polyp
20	3.939	98.0	766	9 ADZ14038	Adz14038 Human dip
21	3.939	98.0	766	9 AEB94223	Aeb94223 CD26/dipe
22	3.933	97.8	736	8 ADD0240	Add0240 Human DPP
23	3.933	97.8	736	5 ABG61910	Abg61910 Prostate
24	3.933	97.8	766	5 AAO15555	Aao15555 Human dip
25	3.933	97.8	766	6 ABP56700	Abp56700 Human liv
26	3.933	97.8	766	7 ADD1045	Add1045 Human src
27	3.933	97.8	766	7 ADN3604	Adn3604 Cancer/lan
28	3.933	97.8	766	8 ADO1940	Ado1940 Human PRO
29	3.929	97.7	766	6 ABP56229	Abp56229 Human dpp
30	3.929	97.7	766	8 ADQ80365	Adq80365 Dipeptidy
31	3.929	97.7	766	9 AEB77579	Aeb77579 Human dip
32	3.928	97.7	766	2 Aar54611	Aar54611 Native CD
33	3.841	95.5	739	2 AAR54613	Aar54613 Delta24-3
34	3.503	87.1	688	8 AD071642	Ado71642 Amino aci
35	3.409.5	84.8	767	3 AAB11748	Aab11748 Rat dippe
36	3.406.5	84.7	767	9 AEB77580	Aeb77580 Rat dippe
37	3.402.5	84.6	767	7 ADD46932	Ad46932 Rat Prote
38	3.395.5	84.5	767	6 ABP56699	Abp56699 Rat liver
39	3.390	84.3	760	8 ADJ76138	Adj76138 Marker_ge
40	3.390	84.3	760	8 ADN9552	Adn9552 Human sol
41	3.390	84.3	760	9 AEB94226	Aeb94226 Mouse CD2
42	3.374	83.9	760	9 AEB77581	Aeb77581 Mouse dip
43	3.3010	74.9	593	2 AAR40916	Aar40916 Sequence
44	3.2175	74.9	593	2 Aar54614	Aar54614 Delta394-
45	2.2175	54.1	734	9 AEB94218	Aeb94218 Human sol
51	2.2168	53.9	760	9 ADW14775	Adw14775 Tumor-agg
52	2.2163	53.8	723	9 AEB94227	Aeb94227 Human sol
53	2.2160	53.7	750	9 AEB94161	Aeb94161 Human sol
54	2.158.5	53.7	761	9 AEB94163	Aeb94163 Mouse sol
55	1.960.5	48.8	759	2 AAW31963	Aaw31963 Human fib
56	1.289.5	32.1	504	5 ADP117327	Adp117327 PolyPeptid
57	1.229	30.6	789	5 ABP53687	Abp53687 Dipeptid
58	1.223	30.4	746	6 ABP55582	Abp55582 Human DPP
59	1.223	30.4	746	6 ABP55584	Abp55584 Human DPP
60	1.223	30.4	746	6 ABP55581	Abp55581 Human DPP
61	1.223	30.4	789	6 ABP55583	Abp55583 Human DPP
62	1.223	30.4	796	6 ABG61593	Abg61593 Human PMM
63	1.223	30.4	796	5 ABB04588	Abb04588 Human am1
64	1.223	30.4	796	5 ABP56224	Abp56224 Human DPP
65	1.223	30.4	796	6 ABP55580	Abp55580 Human DPP
66	1.223	30.4	796	6 ABP55628	Abp55628 Human DPP
67	1.223	30.4	796	7 ADA09104	Ada09104 Novel hum
68	1.223	30.4	796	6 ABP5573	Abp5573 Human DPP
69	1.223	30.4	796	6 AD47758	Ad47758 Human NOV
70	1.217	30.3	798	7 ADJ79028	Adj79028 Human NOV
71	1.217	30.3	798	6 ABP55592	Abp55592 DPP10 pro
72	1.207	30.0	796	6 ABP55591	Abp55591 DPP10 tra
73	1.207	30.0	796	6 ABP55596	Abp55596 DPP10 hom
74	1.198	29.8	743	5 ADP43716	Adp43716 Human Pro
75	1.198	29.8	743	5 ABG61611	Abg61611 Human DPR
76	1.196	29.8	706	5 ABP55578	Abp55578 Mouse DPP
77	1.168.5	29.1	800	6 ABP55579	Abp55579 Mouse DPP
78	1.166	29.0	789	6 ABP55577	Abp55577 Mouse DPP
79	1.166	29.0	796	6 ABP55576	Abp55576 Mouse DPP
80	1.166	29.0	796	7 ADEB58037	Adeb58037 Human Pro
81	1.166	29.0	796	6 ABP55625	Abp55625 Mouse DPP
82	1.166	29.0	797	6 ABP55575	Abp55575 Mouse DPP
83	1.158.5	28.8	799	6 ABP55578	Abp55578 Mouse DPP
84	1.152.5	28.7	691	5 ABG61612	Abg61612 Human DPP
85	1.129	28.1	865	7 ADB79818	Adb79818 Rat dippe
86	1.129	28.1	865	7 ADA09104	Ada09104 Novel cel
87	1.127	28.0	803	6 ADR26259	Adr26259 Novel cel
88	1.127	28.0	865	9 ADB79818	Adb79818 Rat dippe
89	1.119	27.8	804	6 ABP56226	Abp56226 Human dpp
90	1.119	27.8	865	6 ABP56226	Abp56226 Human dpp
91	1.116	27.8	803	7 ADB79818	Adb79818 Rat dippe
92	1.116	27.8	859	7 ADR26329	Adr26329 Novel cel
93	1.116	27.8	859	7 ADB58035	Adb58035 Rat Prote
94	1.116	27.8	859	9 ADR26403	Adr26403 Novel cel
95	1.112.5	27.7	745	4 ABP65409	Abp65409 Drosophil
96	1.089	27.1	804	9 ADR26329	Adr26329 Novel cel
97	1.038	25.8	802	4 ABB71751	Abb71751 Drosophil

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No. Score Query Match Length DB ID Description

Result No.	Score	Query Match	Length	DB ID	Description
1	3.939	98.0	759	2 AAR54612	Aar54612 Delta3-9
2	3.939	98.0	766	2 AAR40509	Aar40509 Sequence
3	3.939	98.0	766	5 ABB08991	Abb08991 Human dip
4	3.939	98.0	766	5 AAG78417	Aag78417 Human dip
5	3.939	98.0	766	7 ADD27855	Add27855 Human dip
6	3.939	98.0	766	7 ADD46334	Add46334 Human Pro
7	3.939	98.0	766	7 ADN32972	Adn32972 Cancer/ an
8	3.939	98.0	766	8 ADJ83981	Adj83981 Human ful
9	3.939	98.0	766	8 ADJ75313	Adj75313 Marker ge
10	3.939	98.0	766	8 ADO1398	Ado1398 Human PRO
11	3.939	98.0	766	8 ADO19806	Ado19806 Human PRO
12	3.939	98.0	766	8 ADO71612	Ado71612 Amino aci
13	3.939	98.0	766	8 ADO71644	Ado71644 Amino aci
14	3.939	98.0	766	8 ABM80355	Abm80355 Tumour-as
15	3.939	98.0	766	8 ADP54458	Adp54458 Human PRO
16	3.939	98.0	766	8 ADU6688	Adu6688 Novel cel
17	3.939	98.0	766	8 ADV25225	Adv25225 Human dip
18	3.939	98.0	766	9 ADY15161	Ady15161 PRO polyp
19	3.939	98.0	766	9 ADY15580	Ady15580 PRO polyp
20	3.939	98.0	766	9 ADZ14038	Adz14038 Human dip
21	3.939	98.0	766	9 AEB94223	Aeb94223 CD26/dipe
22	3.933	97.8	736	8 ADD0240	Add0240 Human DPP
23	3.933	97.8	736	5 ABG61910	Abg61910 Prostate
24	3.933	97.8	766	5 AAO15555	Aao15555 Human dip